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Induction of anesthesia is often associated with hemodynamic instability.  Patients 
undergoing cardiac surgical procedures are at a heightened risk of morbidity and 
mortality due to weakened heart function and thus hemodynamic stability is of paramount 
importance.  Anesthesia providers often base clinical decisions on personal preference 
rather than evidence-based factors.  Decision trees can provide a reference tool to guide 
evidence-based decision-making.  The purpose of this paper was to propose a 
preliminary, evidence-based decision tree to guide in the selection of an appropriate 
intravenous anesthetic for patients undergoing cardiac surgery.  Information Processing 
Theory and PRISMA were used as frameworks to guide the research process and creation 
of the decision tree.  Nine randomized controlled trials published in the last ten years 
were identified and relevant data were extracted and organized into data tables. Quality of 
the studies were evaluated utilizing the CASP method and PRISMA.  A cross-study 
analysis was performed to identify common findings across studies.  Recommendations 
for appropriate interventions at decision points were developed from the cross-study 
analysis.  Advanced Practice Registered Nurses are uniquely qualified to integrate 
evidence-based decision-making tools into everyday clinical practice.  Nursing education 
and nursing practice emphasize using the most current evidence to guide patient care.  
Certified Registered Nurse Anesthetists are looked upon to demonstrate leadership within 
their organizational structures to identify areas for improvement, seek out evidence to 
guide change, and implement that change within their sphere of influence and beyond.  
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Creation of a Preliminary Evidence-Based Decision Tree for Selecting an Intravenous 
Anesthetic for Cardiac Surgery  
 
Background/Statement of the Problem 
During induction of anesthesia, a patient is taken from the pre-procedure state of 
consciousness to a state characterized by lack of consciousness, awareness, and reflexes.  
During this process, patients lose nearly all physiologic self-protection mechanisms.  It’s 
incumbent upon anesthesia providers to utilize the best options available to execute an 
induction with the least chance of negative effects for the patient.  While multiple options 
are available to facilitate induction, the use of intravenous anesthetic medications is the 
most typical technique used with adult patients (Dean & Chapman, 2018).  Despite the 
risks involved and availability of information, anesthesia providers often select particular 
medications based on factors unrelated to individualized patient needs or best practices 
(Munst, Schlapfer, & Biro, 2018).  
Propofol, etomidate, and ketamine are the most commonly used intravenous 
anesthetics in the United States today.  Each of these medications possesses distinct 
mechanisms of action, durations of action, side effects, and risks associated with their 
use.  This information is a component of basic education in anesthetic pharmacology.  
Clinical training reinforces classroom work by providing opportunities during which 
student anesthesia providers witness the effects and patient responses to these 
medications and respond accordingly under the supervision of more experienced 
colleagues.  Patients undergoing cardiac surgery are at much greater risk for 
complications due to underlying cardiac disease and lack of physiologic reserve 
(Contrera, Patterson, & Cushing, 2014).  It’s imperative that the anesthesia provider 
ensure a safe induction for patients and specifically for those undergoing cardiac surgery.   
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 Each anesthetic involves numerous instances where the anesthesia provider must 
choose a suitable intervention in response to an occurrence.  Despite years of training and 
common basic understanding, large variations in practice and decision-making continue 
to cause delays and errors in treatment, many of which result in patient harm (Stiegler & 
Tung, 2014).  Decision-making aids, clinical pathways, and algorithms have been 
developed in most healthcare disciplines to provide practitioners with evidence-based 
tools to assist in selecting the most appropriate intervention in a given situation.  Properly 
tailored, created, and implemented, these tools have been shown to significantly reduce 
morbidity and mortality (Rotter et al., 2012).      
The purpose of this paper was to propose a preliminary, evidence-based decision 
tree to guide in the selection of an appropriate intravenous anesthetic for patients 
undergoing cardiac surgery.   






           A literature review was performed utilizing the research databases Academic 
Search Complete, CINAHL Plus with Full Text, and MEDLINE.  Search terms included 
induction of anesthesia, intravenous induction agents, propofol, etomidate, ketamine, 
cardiac surgery, coronary artery bypass graft, valvular disease, decision making, and 
decision tree, which were searched individually and in combination.  The search was 
limited to articles published in the last ten years.  Reference sections of located articles 
were also mined for additional applicable articles. 
Induction of Anesthesia 
General anesthesia is a state in which a patient is pharmacologically rendered 
completely unconscious and unresponsive to all external stimuli (American Society of 
Anesthesiologists [ASA], 2014).  Under general anesthesia, patients are unable to 
independently support their own airway patency and ventilatory status and often require 
assistance to preserve cardiac and vascular function.  The induction phase is the portion 
of the anesthesia process during which the patient is taken from his/her pre-anesthetic 
state to a state of general anesthesia (Nagelhout, 2014).  Induction of general anesthesia is 
carried out with the administration of either inhalation anesthetics or intravenous 
anesthetics. 
 Inhalation Induction.  The first use of inhalation anesthetics can be traced to the 
mid-1800s, during which the use of ether, chloroform, and nitrous oxide became common 
methods used to induce and maintain general anesthesia (Khan, Hayes, & Buggy, 2014a).  
The effects of inhalational anesthetics were once thought to be directly related to their 
chemical property of solubility in lipids, with those agents expressing a greater degree of 
lipid solubility exhibiting greater potency.  Further research has discovered that the 
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effects of inhalational anesthetics are far more nuanced, with differing mechanisms in the 
spinal cord, above the spinal cord in the brain, at ion channels and nerve synapses, and 
upon particular protein subunits at the molecular level.  Movement into, through, and out 
of the body is primarily related to the lipid solubility of the inhalation anesthetic, but also 
affected by the particular patient’s cardiovascular status, ventilatory function, and amount 
of adipose tissue (Khan et al.). 
 Inhalational anesthetics are not without their risks and side effects.  For example, 
two of the commonly available agents, isoflurane and desflurane, are quite pungent and 
cause airway irritation and coughing, which is troublesome for patients with reactive 
airway disease (Kossick, 2014).  Inhalation anesthetics cause systemic vasodilation 
leading to decreases in mean arterial pressure (MAP) and cardiac output (CO) and can 
generate arrhythmias.  All of the volatile inhalation anesthetics are potent triggers of 
malignant hyperthermia, which is an anesthetic emergency and can lead to fatal 
elevations in body temperature (Kossick).   
             Inhalation induction is accomplished with the exclusive administration of one of 
the volatile anesthetic gases (Dean & Chapman, 2018).  A mask is placed over the face 
and the patient inhales larger concentrations of an inhalation anesthetic than would be 
normally used for the maintenance phase.  Inhalation induction is commonly employed 
with pediatric patients, who are more likely to express fear of needles.  Inhalation 
anesthetics result in a longer induction time and increase the risk of laryngospasm.  With 
the exception of children and those patients with severe aversion to needles, inhalation 
induction has been replaced with intravenous induction in the overwhelming majority of 
cases (Dean & Chapman). 
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 Intravenous Induction.  Similar to inhalation induction, intravenous induction is 
the process by which patients are transitioned to a state of general anesthesia utilizing 
medications that are administered intravenously rather than into the lungs.  Intravenous 
induction produces a faster transition from consciousness to general anesthesia than the 
inhalational method (Nagelhout, 2014).  Intravenous induction also produces a smoother 
process, which is generally more enjoyable for the patient.  Intravenous anesthetics are 
not known to generate laryngospasm and produce a rapid, controlled induction process 
that can be tailored to the specific physiologic demands of each individual (Nagelhout).  
Rapid sequence induction (RSI) is a modified form of intravenous induction whereby an 
intravenous anesthetic is administered, immediately followed by a neuromuscular 
blocking agent to render the patient immediately unconscious and immobile to facilitate 
airway management in patients at greater risk of aspirating stomach contents (Dean & 
Chapman, 2018). 
Intravenous Anesthetics 
Thiopental entered common use in the early 1930s and is generally considered the 
first intravenous anesthetic (Khan, Hayes, & Buggy, 2014b).  A myriad of intravenous 
anesthetics have been developed since, although only four agents, propofol, etomidate, 
ketamine, and thiopentone, are in general use (Dean & Chapman, 2018).  Thiopentone 
was removed from the United States market in 2011, leaving propofol, etomidate and 
ketamine as the intravenous anesthetics most commonly used today (Nagelhout, 2014). 
Propofol.  First patented in 1977 by Roger James and John Glen, propofol was 
introduced in the United States as an intravenous anesthetic in 1989 (Sahinovic, Struys, 
& Absalom, 2018).  It is only soluble in lipid-based emulsions and is formulated to 
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include glycerol, soybean oil, and egg lecithin (Sahinovic et al).  Despite this 
formulation, propofol has been shown to be safe for use in patients with known allergies 
to eggs and soy (Harper, 2016).  Initially, propofol was found to have a propensity for 
harboring bacteria and easily becoming contaminated (Sahinovic et al.).  This problem 
was rectified by the addition of ethylenediaminetetracetic acid (EDTA), which was added 
as a preservative to decrease the incidence of contamination (Sahinovic et al.).  Many 
generic forms of propofol, especially those manufactured outside the United States, 
utilize other preservatives including sodium metabisulfite (Nagelhout, 2014).  This is 
problematic for patients with known sulfite allergies.  Name brand propofol, marketed as 
Diprivan © in the United States, is only available with the EDTA preservative 
(Nagelhout).  Facilities that use generic formulations should keep a small cache of 
EDTA-preserved propofol on hand for use in patients with sulfite allergies.  
Notwithstanding the presence of the preservative, it is generally accepted practice to 
discard any propofol that was removed from its original vial within six hours of doing so 
and to discard any container that has been accessed within 12 hours of opening 
(Nagelhout). 
Pharmacologically, propofol is characterized by a rapid onset due to its high lipid 
solubility (Sahinovic et al., 2018).  The speed with which molecules cross lipid 
membranes is directly related to the lipid solubility characteristics of the molecule.  As 
such, propofol easily crosses the blood-brain barrier (BBB), rapidly inducing a state of 
general anesthesia.  Lipid soluble molecules can cross lipid membranes in both 
directions.  Rapid redistribution of propofol from the brain back into the bloodstream 
accounts for the relatively fast wake-up time after a bolus dose.  Once back in the blood- 
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stream, propofol molecules will deposit into other areas where lipid membranes exist, 
such as adipose tissue (Sahinovic et al.).  Although the therapeutic effects of propofol 
will not generally be observed after redistribution, the body must still metabolize it before 
it is eliminated from the body.  The speed with which this occurs is dependent upon the 
blood supply to the areas in which the molecules were deposited.  If propofol is 
administered as an infusion, the duration of the infusion will determine the extent to 
which molecules are deposited in other areas of the body.  Termed the context-sensitive 
half time, the duration of time necessary for the plasma concentration of propofol to be 
reduced by 50% after stopping the infusion will be longer for infusions of greater 
duration and in patients with a large amount of adipose tissue (Sahinovic et al.).  
Propofol acts upon the γ–amino butyric acid receptor (GABAA) in the central 
nervous system (CNS) (Nagelhout, 2014).  The ligand for that receptor, γ–amino butyric 
acid (GABA), is one of the most important neurotransmitters in the CNS for inhibiting 
neuronal activity.  Upon binding of GABA to GABAA, ligand-gated chloride channels 
open and facilitate the movement of ions, altering membrane potential.  The altered 
membrane potential inhibits depolarization of the neuron, decreasing its activity.  
Propofol does not directly bind to GABAA.  It stimulates the receptor to bind to the 
patient’s own GABA and elicit the response (Nagelhout). 
Upon administration and onset of a dose of propofol, a number of normal 
physiologic mechanisms are depressed (Khan et al., 2014b).  Administration is followed 
by rapid loss of consciousness.  Propofol constricts cerebral blood vessels, leading to a 
decrease in cerebral blood flow (Nagelhout, 2014).  This decrease contributes to a 
lowering of intracranial pressure.  Depression of neuronal activity reduces the cerebral 
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metabolic rate of oxygen consumption (CMRO2) (Nagelhout).  Neuronal depression 
additionally contributes to propofol’s ability to act as an anticonvulsant and antiemetic 
(Sahinovic et al., 2018).  Propofol also exhibits substantial cardiorespiratory changes.  It 
is a direct suppressant of myocardial activity and vascular tone.  As a result, myocardial 
inotropy, arterial vasoconstriction and venous return are all reduced.  Profound 
hypotension and reflex tachycardia can occur.  In induction doses, propofol produces 
apnea, loss of gag reflex, and loss of muscle control of the larynx, which are helpful 
during airway management (Sahinovic et al.).  Direct intravenous injection of propofol 
can cause irritation of the local blood vessel and pain with injection (Nagelhout, 2014). 
Awakening after a dose of propofol is based upon the medication leaving the CNS 
and is virtually unaffected by metabolism of the drug (Nagelhout, 2014).  The liver 
quickly performs phase I metabolism via the cytochrome P450 system, with metabolites 
being conjugated during phase II metabolism by glucuronic acid; the metabolites are 
pharmacologically inactive (Sahinovic et al., 2018).  The demonstrated rate of 
metabolism is in excess of hepatic blood flow.  Propofol metabolism has also been 
demonstrated in the kidneys, small intestines, and lungs.  Greater than 99% of a dose of 
propofol is excreted after metabolism, with a fractional amount excreted in its native 
chemical structure.  The vast majority of the metabolites are excreted by the renal system, 
although small amounts are excreted through the lungs upon exhalation.  In some 
patients, after prolonged exposure to propofol infusions, some of the metabolites can 
discolor the patient’s urine bluish-green (Sahinovic et al.). 
Etomidate.  Etomidate was initially created in the mid 1960’s and became 
commonplace in clinical practice in the early 1970’s (Nagelhout, 2014).  It was originally 
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utilized for treating fungal infections prior to the discovery of its anesthetic capabilities 
(Forman, 2011).  Etomidate’s chemical structure expresses chirality, with two possible 
enantiomers.  Refined preparations of the R(+)-enantiomer have been shown to be 
significantly safer than a racemic mixture.  Commercially available etomidate is supplied 
as the pure R(+)-enantiomer (Forman).   
 Etomidate’s effects are mediated by the GABAA receptor (Forman, 2011).  
Etomidate increases GABA’s affinity for GABAA by binding to a specific location within 
the GABAA receptor (Rathmell & Rosow, 2015).  Etomidate’s pharmacokinetic profile is 
similar to propofol.   Rapid unconsciousness is realized due to etomidate’s high lipid 
solubility and propensity for crossing the BBB (Nagelhout, 2014).  Its action upon 
GABAA receptors stimulates the opening of ligand-gated ion channels, inhibiting 
neuronal activity.  Short duration of action is related to redistribution out of the CNS.  
Metabolism occurs via the cytochrome P450 system to water soluble substances 
(Nagelhout).  All but a small fraction of the metabolites, which have no pharmacologic 
function, are excreted in the urine, with the remainder removed from the body through 
the GI tract as a component of bile (Rathmell & Rosow, 2015).   
Etomidate produces a rather unique pharmacodynamic response.  Etomidate 
causes a constriction of cerebral blood vessels, which produces a reduction in CMRO2 
and intracranial pressure (ICP) (Nagelhout, 2014).  Cerebral perfusion pressure is 
maintained.  When administered as a component of the anesthesia regimen for 
electroconvulsive therapy (ECT), etomidate prolongs the neurologic seizure activity seen 
on electroencephalogram (EEG) (Nagelhout).  Routine administration to patients with a 
known history of epilepsy should be avoided (Rathmell & Rosow, 2015).  Although 
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etomidate has shown to prolong seizure activity during ECT, it has also been shown to 
provide some action as an anticonvulsant and has been used successfully during the 
treatment of status epilepticus.  Etomidate is known for its stable cardiovascular response.  
Stroke volume (SV), heart rate (HR), and cardiac output (CO) are maintained, while a 
slight decrease in systemic vascular resistance (SVR) may occur.  Etomidate’s stable 
cardiovascular profile has led to its common use in patients with depressed heart 
function, severe trauma, and other clinical situations involving hemodynamically 
compromised patients.  Etomidate has been demonstrated to depress myocardial 
contractility; however, quantities needed to elicit this response far exceed the therapeutic 
dose (Rathmell & Rosow).  The baroreceptor reflex and sympathetic tone are maintained 
(Nagelhout, 2014).  Arrhythmias of any clinical significance are rare.  Patients carrying 
diagnoses of mitral or aortic valve pathologies may experience acute hypotension after 
receiving Etomidate.  With the exception of a possible transitory period of apnea after the 
administration of an induction dose, respiratory rate is maintained.  Histamine is not 
released in response to administration and there is no effect on bronchial smooth muscle 
(Nagelhout). 
Etomidate produces some adverse effects that must be weighed against its 
benefits and may limit use in certain patients.  The most significant adverse effect of 
etomidate is its inhibition of steroid synthesis by the adrenal glands (Erdoes, Basciani, & 
Eberle, 2014).  Etomidate is a potent inhibitor of 11 β-hydroxylase, a microsomal enzyme 
of the cytochrome P450 system, which is responsible for a critical step in the cascade of 
reactions that produces cortisol.  Adrenal inhibition is greater than the anesthetic effect 
for a given dose and can continue for 24-72 hours in some patients.  This has resulted in 
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the discontinuation of etomidate for long-term intravenous infusions in critically ill 
patients (Erdoes et al.).  Mixed results from several randomized studies have created 
controversy about its use in bolus doses in patients for whom a depressed adrenal stress 
response could prove detrimental (Nagelhout, 2014).  Studies examining the efficacy of 
supplementing affected patients with exogenous steroids have also demonstrated mixed 
results (Nagelhout).  Etomidate also causes myoclonus, which is an episode of 
involuntary muscle contractions sometimes misinterpreted as seizure activity.  This is 
thought to be a result of disparate timing of action in certain parts of the brain, during 
which inhibitory neurons are anesthetized prior to excitatory neurons, resulting in 
overexcitation of the excitatory pathways (Nagelhout).  This usually has little clinical 
significance, as etomidate is routinely accompanied by medications that produce 
neuromuscular blockade and skeletal paralysis.  Patients experience pain at the site of 
injection and etomidate has been directly linked to post-operative nausea and vomiting 
(PONV) (Forman, 2011). 
 Another important physiologic effect that must be considered is the relationship 
of etomidate to the condition porphyria.  Porphyrias are genetically inherited or acquired 
metabolic disorders resulting in a decreased supply of an enzyme required to synthesize 
heme, a foundational component of the hemoglobin molecule (Nagelhout, 2014).  
Porphyrins are chemical precursors to heme, which can cause neurologic damage if they 
accumulate in high doses.  Etomidate is an inducer of the enzyme ALA-synthetase, the 
enzyme that catalyzes as the rate-limiting step in the cascade of reactions that produce 
heme.  Induction of ALA-synthetase increases the rate of production of porphyrins.  The 
patient with a porphyria cannot maintain a heme production rate equivalent to the rate of 
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porphyrin production, causing them to accumulate.  Etomidate is contraindicated in 
patients with a recognized porphyria (Nagelhout).  
Ketamine.  Various sources report the first use of ketamine in the clinical setting 
sometime in the mid-1960s to early 1970s (Khan et al., 2014b; Nagelhout, 2014).  
Ketamine is a hydrophilic molecule that contains a single chiral carbon, with two possible 
enantiomers (Rathmell & Rosow, 2015).  The racemic mixture of both enantiomers is the 
primary formulation that is commercially available.  A pure formulation of the S(+)-
enantiomer exists but is not in common use.  S(+)-ketamine was found to offer superior 
desired effects with fewer untoward reactions (Rathmell & Rosow).  S(+)-ketamine has 
been found to offer only trivial clinical benefits that don’t justify the costs associated with 
isolating the pure preparation (Nagelhout, 2014). 
 Ketamine’s mechanism of action is substantially dissimilar to that of propofol or 
etomidate (Nagelhout, 2014).  The primary site of action is at the N-methyl-D-aspartate 
(NMDA) receptor, although it has been shown to display effects at other receptors as 
well, including adenosine, cholinergic, monoamine, opioid, and purinergic receptors.  
Ketamine also alters gene expression of interleukin-6 (IL-6) and tumor necrosis factor-
alpha (TNF-α), providing some anti-inflammatory effects.  Ketamine can also be used for 
its direct analgesic properties, whereby it blocks the transmission of pain in the dorsal 
horn of the spinal cord (Nagelhout).  Ketamine’s actions at the GABAA receptor is 
negligible (Rathmell & Rosow, 2015).  One of Ketamine’s main benefits is its 
compatibility with multiple routes of administration in addition to the intravenous route.  
It can be administered via the intraosseous, intramuscular, intranasal, and oral routes; a 
Ketamine lozenge is also available (Marland et al., 2013). 
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 Ketamine’s high lipid solubility leads to it easily crossing the BBB, leading to 
rapid unconsciousness, followed by redistribution out of the CNS leading to a short 
duration of action (Rathmell & Rosow, 2015).  Metabolism is carried out by the 
cytochrome P450 system in the liver.  The principal metabolite of ketamine is 
norketamine, which has active pharmacologic effects, prolonging the effects at receptors 
outside the CNS.  Phase II metabolism conjugates norketamine into an inactive 
hydrophilic compound, promoting renal elimination.  Ketamine serves to induce the 
cytochrome p450 enzymes responsible for its metabolism, accelerating its elimination 
half-life over time.  Tolerance can develop with prolonged use (Rathmell & Rosow). 
 Ketamine produces a wide array of pharmacodynamic effects.  Intravenous 
administration of an induction dose creates a state of dissociative anesthesia, whereby the 
patient enters a catatonic state (Nagelhout, 2014).  The patient does not interact with the 
environment but may appear awake.  Central nervous system reflexes, including corneal 
and pupillary reflexes, are maintained.  A cardinal sign of Ketamine administration is 
nystagmus.  Patients can sneeze, cough, and swallow, while maintaining airway 
protective reflexes.  Ketamine administration is accompanied by increased oral 
secretions, which increases the possibility of laryngospasm in the setting of preserved 
airway reflexes.  Ketamine dilates cerebral blood vessels, leading to an increase in 
cerebral blood flow (CBF), CMRO2 and ICP.  Ketamine is generally avoided in patients 
at risk for increased ICP (Nagelhout).   
Ketamine’s desirability in critically ill patients is related to its cardiovascular 
effects. Ketamine causes sympathetic stimulation of the myocardium, resulting in 
increases in HR, CO, and SVR (Rathmell & Rosow, 2015).  Myocardial workload 
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intensifies, which increases myocardial oxygen demand.  Blood pressure (BP) in the 
pulmonary circuit and system circuit are augmented.  Serum lactate levels may increase 
(Rathmell & Rosow).  A different medication should be chosen for patients who struggle 
to control their BP, or for those with a known history of ischemic heart disease (Khan et 
al., 2014b).  Ketamine is not a catecholamine, so does not directly stimulate adrenergic 
receptors in the heart or blood vessels (Rathmell & Rosow, 2015).  Ketamine’s 
sympathomimetic effects are likely derived from the stimulation of endogenous 
catecholamines or interfering with their reuptake.  Patients suffering from catecholamine 
depletion have demonstrated cardiac depression after receiving ketamine.  Respiratory 
depression is insignificant, other than transient apnea following swift administration of an 
induction dose.  Ketamine causes bronchodilation and is considered the most desirable IV 
induction agent for patients experiencing symptomatic reactive airway disease (Rathmell 
& Rosow).  Several international organizations have published recommendations that 
include ketamine as the first or only choice of IV anesthetic in emergency situations, 
trauma, and in developing countries (Morris, Perris, Klein, & Mahoney, 2009). 
Adverse reactions limit the use of ketamine in certain situations.  Emergence 
delirium, with concomitant auditory and visual hallucinations, temporary blindness and 
vivid dreams, commonly occurs (Rathmell & Rosow, 2015).  Acute schizophrenia and 
other psychotic symptoms have been reported (Marland et al., 2013).  Ketamine has been 
shown to lower the incidence cognitive dysfunction in patients undergoing cardiothoracic 
surgical procedures (Hudetz et al., 2009).  The safety of ketamine in patients with 
porphyrias is controversial; use should be reserved for situations in which the benefits far 
outweigh the risks (James & Hift, 2000).  
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Anesthesia Induction for Cardiac Surgery 
 Cardiac surgery can present a challenging set of circumstances for the anesthesia 
provider.  Patients often come to surgery with a myriad of coexisting diseases, while 
cardiovascular status has deteriorated to the point that surgical correction is required.  
Tight control of hemodynamic stability is essential while accounting for existing 
comorbidities and pharmacologic side effects (Mittnacht, London, Puskas, & Kaplan, 
2018).  Selection of the appropriate IV anesthetic will be guided by the pathophysiology 
of the particular cardiac condition for which the patient requires repair. 
 Valvular Disease.  Blood travels through a valve as it exits each chamber of the 
heart.  Properly functioning, valves prevent retrograde blood flow while permitting 
unimpeded antegrade flow, generating a predictable pressure/volume relationship in each 
chamber (Contrera et al., 2014).  While disease in the valves of the left heart are 
common, valve disease in the right heart is considerably less likely (Contrera et al.).  
Cardiovascular sequelae from valve disease can include structural changes such as 
hypertrophy, arrhythmias, and frank cardiac failure (Herrera, 2018).  Diseased valves can 
either fail close properly (regurgitation) or fail to open completely (stenosis).  The 
structural changes and symptomatology differ according to valve and pathology.  
Anesthesia providers must choose the appropriate medications based upon the particular 
valve involved, the type and severity of the valve condition, and the cardiovascular 
pharmacodynamics of the particular drug (Herrera). 
 Aortic Stenosis.  The most commonly occurring valve disease in the 
industrialized world, aortic stenosis is a condition in which the aortic valve is unable to 
open completely (Contrera et al., 2014).  While usually a result of calcification of the 
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valve, a small segment of the population is born with a bicuspid valve (a normal valve 
has three cusps), which is more likely to stenose (Herrera, 2018).  Patients with a 
bicuspid valve develop symptoms earlier in life and often require surgical correction at a 
younger age (Herrera). 
 In response to the decreased movement of blood into the systemic circulation, the 
heart compensates by generating more pressure in the left ventricle to maintain cardiac 
output (Herrera, 2018).  The structural response is consistent with increased workload by 
any muscle group, in that it stiffens and hypertrophies.  The hypertrophied left ventricle 
balances the strength of contraction with the degree of stenosis to maintain a pressure 
gradient on either side of the valve.  The additional workload on the heart muscle 
substantially increases oxygen demand (Herrera).  The hypertrophied ventricle cannot 
relax appropriately, leading to diastolic heart failure (Paul & Des, 2017).   
Anesthetic management of aortic stenosis involves maintaining the pressure 
gradient between the left ventricle and the aorta (Contrera et al., 2014).   Emphasis must 
be placed on preserving adequate preload, maintenance of synchrony between the atria 
and ventricles, assuring sufficient time for ventricular filling, and preventing abrupt 
reductions in systemic blood pressure.  Volume replacement may be necessary to provide 
enough preload to expand the stiffened ventricle.  Tachycardia decreases the time spent in 
the diastolic phase of the cardiac cycle, leading to insufficient ventricular filling time.  
Conversely, bradycardia drops overall cardiac output, which may not meet the demands 
of systemic circulation (Contrera et al., 2014).  The atria provide nearly half of the overall 
cardiac output in the setting of aortic stenosis (Paul & Des, 2017).  Loss of 
atrioventricular synchrony, as can occur with atrial fibrillation, will cause significant 
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declines in left ventricular ejection.   Systemic hypotension must not be permitted to 
occur and afterload must be maintained.  A decrease in the pressure gradient across the 
stenotic valve will interfere with diastolic coronary artery filling and ischemia will result 
(Paul & Des).  The best choice of induction agent will maintain SVR while preserving 
cardiac function and preventing arrhythmias or large changes in heart rate (Herrera, 
2018). 
Aortic Regurgitation.  Failure of the aortic valve to completely close during 
diastole permits blood to regurgitate into the left ventricle (Contrera et al., 2014).  The 
consequences are twofold.  First, systemic cardiac output is decreased, as a portion of the 
blood that was ejected returns to the left ventricle through the incompetent valve.  
Second, increased diastolic volume, (regurgitant flow plus atrial flow) causes the 
ventricle to enlarge to accommodate it (Contrera et al.).  The ventricle will hypertrophy 
and increase wall tension over time to generate the pressures needed to eject the increased 
volume in sufficient quantity to maintain cardiac output (Paul & Des, 2017).  Prolonged, 
untreated aortic regurgitation can exceed the ability of the heart to compensate, resulting 
in systolic heart failure (Paul & Des).  The best induction agent will maintain or slightly 
increased HR while lowering SVR (Herrera, 2018).  Higher heart rates decrease 
ventricular filling time, preventing an excessive dilation of the chamber.  Decreased 
afterload lowers the pressure against which the heart must pump to maintain cardiac 
output, decreasing workload. 
Mitral Stenosis.  Mitral stenosis is the result of a failure of the mitral valve to 
open completely during diastole (Contrera et al., 2014).  It is not very common in the 
industrialized world and is overwhelmingly associated with rheumatic heart disease.  
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Pressure increases in the left atrium causing dilation and backward pressure into the 
pulmonary circulation.  Similar to mitral regurgitation, atrial fibrillation, pulmonary 
hypertension, and right heart failure can occur.  The chief insult to cardiac function with 
mitral stenosis is a deficit in left ventricular filling through the narrowed valve opening 
(Contrera et al.).  Systemic vascular resistance should have little effect on overall cardiac 
function, as mitral stenosis has little effect on left ventricular function (Herrera, 2018).  
Choice of IV anesthetic should be directed at maintaining or decreasing heart rate to 
prolong diastolic filling time and augment left ventricular preload (Herrera). 
Mitral Regurgitation.  Mitral regurgitation is a result of backward flow of blood 
through an incompletely closed valve (Contrera et al., 2014).  The mitral valve is 
normally closed during the systolic phase of the cardiac cycle.  Mitral regurgitation 
permits backward flow of blood into the left atrium when the left ventricle contracts.  
Backflow into the atria, coupled with forward flow from the pulmonary circulation, 
causes increases in volume and pressure in the left atrium.  Dilation of the left atrium 
interferes with conduction of action potentials.  As a result, mitral regurgitation is often 
accompanied by atrial fibrillation (Contrera et al.).  Continuous blood supply from the 
right heart and regurgitation into the left atrium will ultimately lead to increased left heart 
and ultimately left ventricular volume (Paul & Des, 2017).  Left untreated, chronic mitral 
regurgitation will lead to systolic heart failure; this will extend the increased backpressure 
through the left atrium, into the pulmonary circulation, and into the right heart, leading to 
right heart failure (Paul & Des).  Choice of IV anesthetic is guided by similar factors as 
with aortic regurgitation (Herrera, 2018).  Decreasing SVR will lessen the pressure 
against which the heart must pump to maintain cardiac output.  Maintaining or slightly 
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increasing heart rate will shorten the duration of ventricular filling, minimizing excessive 
left ventricular pressure, and therefore decreasing the degree of retrograde flow (Herrera).          
 Coronary Artery Disease.  Coronary artery disease (CAD) takes a significant 
toll on the health of Americans.  It is one of the leading causes of death in the United 
States, and the incidence of CAD is increasing (Mittnacht et al., 2018).  Hundreds of 
thousands of people undergo coronary artery bypass grafting (CABG) procedures 
annually.  Coronary artery disease is the end-result of numerous physiologic processes 
that contribute to the narrowing of the lumen of the arteries that provide oxygenated 
blood to heart muscle cells (Contrera et al., 2014).  Decreased lumen size leads to 
decreased oxygen supply.  Oxygen consumption is determined by combined effects of the 
rate at which the heart beats, the strength of contraction, and the stress exerted against the 
walls of the heart chambers by internal pressure (Hibbert, Nathan, Simard, & O’Brien, 
2018).  If oxygen demand exceeds supply, patients can experience symptoms including 
chest pain and dyspnea (Contrera et al., 2014).  Patients with long-standing ischemic 
heart disease may also possess comorbid systolic heart failure and reduced ejection 
fraction.  These patients have even less cardiac reserve and may lack the ability to 
compensate for even the slightest insult to their hemodynamics (Contrera et al.). 
 While there are many considerations to be made throughout the course of an 
anesthetic for CABG, preventing ischemia remains the primary concern during the 
induction phase.  Ischemia prevention is accomplished by preservation of the patient’s 
myocardial oxygen supply versus demand, ensuring that demand doesn’t exceed supply 
(Mittnacht et al., 2018).  Selection of an IV anesthetic for CABG should focus on 
maintenance or optimization of the patient’s pre-operative hemodynamic status (Contrera 
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et al., 2014).  Tachycardia will increase myocardial oxygen demand.  Bradycardia may 
prevent the heart from producing sufficient cardiac output and coronary artery perfusion 
may suffer.  Sustaining the BP as close to baseline as possible is optimal.  Hypertension 
increases the amount of work the heart must do to overcome afterload and sustain cardiac 
output.  Hypotension is least desirable, resulting in decreased coronary perfusion and 
oxygen supply.  Increased inotropy will increase oxygen demand, while decreasing 
contractility, if tolerated, will reduce it.  The best IV anesthetic for CABG will be the 
choice that achieves a smooth induction while preventing tachycardia and maintaining a 
stable BP commensurate with the patient’s baseline (Contrera et al.). 
Decision-Making in Anesthesia 
 Substantial incongruence exists in healthcare decisions made by different 
practitioners pertaining to the same question (Cozmuta, Merkel, Wahl, & Fraenkel, 
2014).  Often, subject matter experts cannot agree on the proper treatment course.  The 
outcomes of these decisions can have significant consequences depending on the 
situation and any confounding factors involved (Cozmuta et al.).  Medical error is 
commonplace, often with grave consequences (Stiegler & Tung, 2014).  Errors frequently 
lead to delays in care, especially in high pressure environments.  When errors occur, they 
may be accompanied by greater magnitudes of morbidity or mortality and can lead to 
litigation.  Real-world investigations and simulated patient scenarios have demonstrated 
large variations and inconsistencies in decision-making, as well as failure to adhere to 
accepted practice, and in some instances, treatment guidelines created by recognized 
experts or professional associations.  In the anesthesia profession, these weaknesses 
affect novices and specialists alike (Stiegler & Tung). 
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 In a prospective, nonrandomized cohort study conducted by Munst et al., (2018), 
senior physician anesthesiologists selected an IV anesthetic that the authors termed 
“unjustified” based on accepted pharmacologic principles in one out of every three cases.   
Medical decisions should be based upon conditions specific to the patient and the 
procedure.  Often, personal preference, facility custom, budgetary or other non-medical 
motivations take precedence over sound science and accepted standards of practice.  
Decisions made by assigning primacy to factors that are not based on sound 
pharmaceutical science and in the patients’ best interest places patients at undue risk.  
This is true even if no harm comes to the patient, or any possible adverse reactions can be 
easily dispensed with by the anesthesia provider (Munst et al.). 
   Several decision-making models have been examined for the manner in which 
their tenets apply to the field of anesthesia (Stiegler & Tung, 2014).  A common theme in 
some of the oldest decision-making models is to consider the cost versus benefit of each 
medical decision and assess the potential consequences.  Practitioners must be cognizant 
that all of the information necessary to make that determination may not be available.  
Patient and practitioner priorities may also differ (Stiegler & Tung, 2014).  Providers may 
gravitate toward the solution that can be accomplished in the least time with the least cost 
while not incurring undue risk, while the patient may prefer the safest, most comfortable 
option regardless of the cost or time involved.   
Pattern-matching is commonly employed as a mechanism for decision-making 
and used as a framework in medical education (Stiegler & Tung, 2014).  Providers 
consider the decisions they have made, or they have seen others make in similar 
situations before without consequence, leading them to believe that the same decision is 
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applicable in all similar circumstances.  This, and other intellectual shortcuts, sacrifice 
rationality for convenience and thus risk grave errors in decision-making or failure to 
recognize a life-threatening situation (Stiegler & Tung).  This is especially noteworthy in 
situations where the provider lacks a complete information set related to the patient or 
procedure (Munst et al., 2018).  Critical decisions in time-sensitive situations are more 
likely to be made purely on instinct, especially when the clinician feels that taking time to 
consider all possible choices and outcomes is impractical (Stiegler & Tung, 2014).   
A number of biases have been cited as root causes of medical errors and can 
weigh considerably on the decision-making process (Stiegler & Tung, 2014).  Human 
nature is to seek out information that confirms one’s own conclusions rather than a 
perspective challenging the legitimacy of an action.  In a collaborative practice 
environment, some providers may hesitate to question the decision of a senior colleague 
or offer an alternative therapy, even when armed with a vital piece of information.   
Experience and prestige can lead to excessive self-assuredness, blinding providers to the 
possibility of other choices or failure to seek assistance when necessary.  This may be 
most evident when senior practitioners refuse to adopt a safer method of performing a 
skill for which they have realized historical success in the face of evidence demonstrating 
the superiority of the new method.  Practitioners who draw their primary decision-making 
influence from past experience are also vulnerable to the idea that their memory does not 
mirror the details of the comparable event (Stiegler & Tung).   
Additional biases that influence decision-making relate to the manner in which 
the provider views the possible outcomes of the decision (Stiegler & Tung, 2014).  
Emotion can play a significant role in decision-making.  A provider may avoid a correct 
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decision if they have experienced a negative outcome when using a particular 
intervention in a similar situation.  Decisions believed to produce positive results will 
always be preferred to those believed to produce negative consequences (Stiegler & 
Tung).  There is considerable variability in how a negative experience influences a 
practitioner’s future decision-making processes (Cozmuta et al., 2014).  Particularly in 
the practice of anesthesia, there is little in the way of patient contact after discharge and a 
thorough case review is rarely undertaken absent an obvious complication or sentinel 
event.  Lacking any information to the contrary, decisions will be assumed to have been 
correct and the desired outcome achieved (Stiegler & Tung, 2014). 
The rationale behind a clinical decision is equally important as the decision itself 
(Stiegler & Tung, 2014).  Making the correct decision based on reasoned thinking in 
context with training and experience develops competence.  Choosing the correct 
intervention for the incorrect reason is simply a case of good luck and can easily lead to a 
different result under different circumstances.  Understanding all of the factors that 
influence the decision-making process improves the likelihood that providers will 
recognize illogical factors influencing their behavior, guiding them to a more reasoned 
and scientifically based choice.  The use of cognitive aids has been shown to minimize 
the likelihood that the decision-making process will be negatively prejudiced by outside 
factors more likely to lead to an incorrect judgement (Stiegler & Tung).  Decision trees 
are one such cognitive aid.     
Decision Trees in Evidence-Based Practice 
 Decision trees provide a logical, orderly framework that can be used by clinicians 
to evaluate the factors that impact a decision and guide them to the appropriate choice 
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(Lee et al., 2009).  Appropriate utilization of evidence-based practice (EBP) is not merely 
the regurgitation of findings from a particular study and applying them to all patients.  
The individual complexities of each patient and each situation requires clinical judgement 
to interpret the best evidence and relate it to the individual.  Often, several decision points 
are navigated on the pathway to the eventual choice (Lee et al.).   
 Decision trees provide a mechanism for identifying the available options and 
considering the possible consequences of each step in the decision-making process 
(Bamber & Evans, 2016).  Even in the face of limited evidence, a properly tailored 
decision tree affords the clinician a mechanism for considering what is available without 
the need to perform a literature search on the spot.  The evidence-based information in 
the decision tree serves to augment the knowledge and experience of the clinician and is 
superior to choosing a therapy on conjecture alone.  The transparency provided is one of 
the decision tree’s greatest assets.  In some settings, the patient can be consulted to 
determine their priorities, and collaborate with the provider to provide safe, 
individualized care.  Decision trees may be most beneficial in situations where there are 
few alternatives and the incorrect choice will put the patient in jeopardy (Bamber & 
Evans).  Implementation of a decision tree assists practitioners to consider all of the 
relevant facts, especially those that may not be routinely anticipated (Lee et al., 2009).   





The theoretical frameworks for this project were the Information-Processing 
Theory (IPT) and the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA).  Initially applied to cognitive decision making in healthcare in the 
late 1970’s, IPT (Figure 1) encourages clinicians to consider theories for a particular 
situation, place them in context with a given set of variables, confirm or refute the theory, 
and utilize the best applicable information to guide care (Joseph & Patel, 1990).  Clinical 
information is collected and distilled through the clinician’s body of knowledge and 
experience.  These factors guide the initial plan, which is refined based on any other 
pertinent information the clinician seeks out.  The applicability of each data point is 
considered and weighed in terms of its contribution to the whole and the processed 
information directs the decision.  This framework assists clinicians in combining 
experience, diagnostic reasoning, scientific evidence, and logic to deduce the appropriate 
intervention from the options available and is commonly used in clinical decision-making 
and the creation of decision trees (Banning, 2008).  
 
Figure 1. Information Processing Theory (Information Processing Model, n.d.) 
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Information Processing Theory correlates to the concept of decision-making in 
anesthesia, as it parallels the traditional methods of information gathering and treatment 
selection in common use.  A complete medical history is obtained for all patients 
receiving anesthesia as a standard of care (American Association of Nurse Anesthetists 
[AANA], 2019).  Anesthetists begin to formulate their treatment plan based upon the 
information obtained.  The anesthetist then conducts an in-person interview and physical 
assessment of the patient to gather additional pertinent information.  The body of clinical 
data is reviewed in the context of the planned surgical procedure, and with the exception 
of any unforeseen circumstance that requires modification, the plan of care is finalized 
(AANA). 
The current pace of turnover in the operating theater is one of many factors that 
contributes to lapses in patient safety, medication errors and other adverse events 
(Eichhorn, 2013).  In situations of increased pressure, people take short cuts.  Medication 
selection may be determined based on comfort of the anesthesia provider rather than what 
is best for the patient.  The induction phase is a crucial time in anesthesia care during 
which errors in judgement can prove fatal to a patient.  Utilizing the tenets of IPT, the 
preliminary steps can be undertaken to create an evidence-based decision tree to guide in 
the selection of an appropriate intravenous anesthetic for patients undergoing cardiac 
surgery. 
Additionally, the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) was used.  Adapted from the Quality of Reporting of Meta-analyses 
(QUORUM) statement, PRISMA provides a comprehensive process through which an 
author can identify, track, evaluate and report relevant research obtained through 
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randomized controlled trials (RCTs) (Moher, Liberati, Tetzlaff, Martin, & The PRISMA 
Group, 2009).   
Preferred Reporting Items for Systematic Reviews and Meta-Analyses utilizes a 
flow diagram (Figure 2) to assist the author in reporting the process used to select the 
studies used to complete a systematic review (Moher et al., 2009).  The flow diagram is 
useful in demonstrating the breadth of the literature search conducted as well as 
accounting for the dispensation of any studies excluded from the review.  Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses also utilizes a 27-question 
checklist (Figure 3) for reporting on each research study included in a systematic review 
(Moher et al.).  The deployment of this checklist ensures that a consistent and transparent 
process is used, so that reporting for each study is similar.  Transparency in the research 
process, combined with consistency in evaluation and reporting of included studies, 
lowers the likelihood of publication bias (Moher et al.).    















The purpose of this paper was to propose a preliminary, evidence-based decision 
tree to guide in the selection of an appropriate intravenous anesthetic for patients 
undergoing cardiac surgery. 
Design 
This was an evidence-based project designed to create a decision tree.  Evidence 
was gathered, evaluated, analyzed, and reported in a manner similar to that which is used 
to perform a systematic review. 
Inclusion/Exclusion Criteria 
Inclusion criteria for this systematic review included RCTs only.  All patients 
included in the trial were required to be adults (greater than 18 years of age), be 
undergoing cardiac surgery with no other included procedure, and have anesthesia 
induced via the intravenous route utilizing a single intravenous anesthetic.  All patients 
must have received either propofol, etomidate, or ketamine for induction.  All of the 
RCTs must have been published within the last ten years, written in English, and 
published in a peer-reviewed journal. 
Exclusion criteria included any article published greater than 10 years ago or 
written in a language other than English.  Additional exclusion criteria included any 
patients under age 18, patients receiving an inhalation induction, studies that don’t 
compare propofol, etomidate or ketamine to one of the other of these three medications, 






 A comprehensive literature search was conducted utilizing the databases 
CINAHL, Academic Search Premier, Medline and PubMed.  Search terms included 
“induction of anesthesia”, “propofol”, “etomidate”, “ketamine”, “cardiac surgery”, and 
“coronary artery bypass grafting”.  After removing duplicates, articles were screened for 
eligibility.  Articles meeting eligibility criteria were included in the data collection 
process.  The search process and results were summarized in a PRISMA Flow Diagram 
(Appendix A). 
Data Collection 
 Studies selected for this systematic review were evaluated utilizing the PRISMA 
Checklist as a guide.  Data collected from each study was summarized in a table created 
by the author (Table 1) and included in Appendix B.   
Table 1 
Data Collection Table 
Purpose Project Design Site, Sample Method Results Limitations 
      
 
Outcome measures for each study were extracted and summarized in a table 








Table 2  
Outcome Measures Table 
 Propofol Etomidate Ketamine 
Heart Rate    
Systolic Blood Pressure    
Diastolic Blood Pressure    
Mean Arterial Pressure    
Cardiac Output    
Cardiac Index    
SVR    
Endocrine Response    
 
Critical Appraisal 
 Critical appraisal of each study was carried out using the Critical Appraisal Skills 
Programme (CASP).  Critical Appraisal Skills Programme was developed to assist 
researchers by providing an organized method for evaluating evidence to determine 
quality (Singh, 2013).  When using evidence to change practice, the recommendations are 
only as strong as the evidence used.  Critical appraisal of research gauges the reliability 
of the methodology and findings of a study.  Studies conducted using the incorrect 
methods for the study design, improper statistical analysis techniques, and suspect 
reporting practices are not acceptable for the basis of guiding clinical practice.  Each 
study was critically appraised utilizing the CASP checklist shown in Table 3 and 





CASP Checklist for Randomized Controlled Trials 
A) Are the results of the trial valid? YES CAN’T TELL NO 
1. Did the trial address a clearly focused 
issue? 
   
2. Was the assignment of patients to 
treatments randomized? 
   
3. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
   
4. Were patients, health workers, and 
study personnel “blind” to treatment? 
   
5. Were the groups similar at the start of 
the trial? 
   
6. Aside from the experimental 
intervention, were groups treated 
equally? 
   
B) What are the results?  
7. How large was the treatment effect?  
8. How precise was the estimate of the 
treatment effect? 
 
C) Will the results help locally? YES CAN’T TELL NO 
9. Can the results be applied in your 
context? (or to the local population?) 
   
10. Were all clinically important outcomes 
considered? 
   




 Results were analyzed across studies utilizing Table 2 to determine overall 
outcomes, themes and significance of findings.  The findings of the cross-study analysis 
were utilized to guide the preliminary creation of an evidence-based decision tree to 
guide in the selection of an appropriate intravenous anesthetic for patients undergoing 
cardiac surgery.  The process used will be described in the results section. 




 Based upon the inclusion and exclusion criteria explained above, nine articles 
were identified and included in this review.  The process used to identify, screen, and 
select the included articles is represented graphically in Appendix A.  All of the included 
articles are RCTs comparing one of the chosen IV anesthetics to another of the chosen IV 
anesthetics during the induction phase of general anesthesia.  Study-specific data were 
extracted from each article and are included in Appendix B.  Outcome measures and 
results were extracted from each article and are included in Appendix C.  Each article  
was evaluated for quality using the CASP Checklist for Randomized Controlled Trials, 
which are included in Appendix D.  Finally, a cross-study analysis was performed to 
compare and contrast the findings of each article and is included in Appendix E. 
Individual Study Analysis 
 The study performed by Basagan-Mogol et al. (2010) (Appendix B-1) was a 
randomized controlled trial to evaluate the hemodynamic and analgesic effects of 
ketamine by comparing it with propofol.  All patients were undergoing CABG 
procedures.  Thirty patients were randomly assigned to two groups.  Patients assigned to 
group K received 2 mg/kg of ketamine as their IV induction agent.  Patients assigned to 
group P received 0.5 mg/kg of propofol as their IV induction agent.   All patients 
received standardized weight-based doses of morphine, midazolam, fentanyl, and 
rocuronium during the induction process.  Laryngoscopy was performed and intubation 
was achieved using the same process in all patients.  All patients were monitored using 
the same invasive and non-invasive modalities.  Anesthesia was maintained utilizing 0.5-
2% sevoflurane.  Adjustments to sevoflurane doses were made based upon the same 
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hemodynamic parameters in all patients.  Data were recorded at the same time intervals 
in all patients. 
 Data were analyzed using the SPSS software platform to determine the mean and 
standard deviation for each outcome measure.  The Wilcoxon signed rank test was used 
to evaluate deviations from baseline for each outcome measure.  The Mann-Whitney U-
test and the Kruskal Wallis test were used to compare values between the study groups.  
The authors defined p < 0.05 as significant.  The authors found significant decreases in 
MAP and SVR one minute after induction in group P (Appendix C-1).  The authors 
reported that there were no adverse hemodynamic events or ST-segment abnormalities 
during the study, nor was any evidence found that ketamine clearly contributed to the 
level of analgesia.   
 Critical appraisal of this study can be found in Appendix D-1.  The study 
addressed a clearly focused issue.  The assignment of patients to each group was 
randomized and all patients were properly accounted for at the conclusion of the trial.  
There was no indication as to the method used to randomize the participants, nor was 
there any indication that the patient or anesthesia providers were blinded to the study 
medication.  The article does report that the observer responsible for recording 
measurements was blinded to the study medication.  The groups were similar, and with 
the exception of the experimental intervention, the groups were treated equally.  The 
treatment effect was not discussed.  The results can be applied to the local population.  
All clinically important outcomes were considered.  No harmful effects were reported 
from the study intervention.  Based upon their findings, the authors concluded that 
ketamine provided more hemodynamic stability, and was therefore superior to propofol. 
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 The study by Pandey et al. (2012) (Appendix B-2) was a randomized controlled 
trial in which the effects of propofol on hemodynamic parameters and serum cortisol 
levels were compared with etomidate in patients with normal left ventricular function.  
All patients were undergoing elective CABG procedures on cardiopulmonary bypass 
(CPB).  One hundred patients were randomly assigned to two groups.  Patients assigned 
to group E received 0.2 mg/kg of etomidate as the IV induction agent.  Patients assigned 
to group P received 2.0 mg/kg or propofol as the IV induction agent.  All patients 
received similar weight-based doses of morphine, phenergan, midazolam, fentanyl, and 
rocuronium, which were administered within the same time frame prior to and during the 
induction process.  All patients were monitored using the same invasive and non-invasive 
modalities.  Once induced, anesthesia was maintained using sevoflurane.  Data points 
were recorded for the same hemodynamic parameters and cortisol levels at the same time 
intervals respectively for all patients. 
 Statistical analysis was performed using the STATA 9.0 software platform and 
data were summarized using a percentage or a range as the particular parameter required.  
Baseline categorical variables were compared using the Fisher’s exact test.  Baseline 
continuous variables were compared using the Student’s t test.  Between-group 
hemodynamic variables were compared using the Student’s t test for independent 
variables.  The Wilcoxon Rank Sum test was used to analyze between-group data 
concerning serum cortisol.  The authors identified a value of p < 0.05 as a significant 
finding.  Outcome measures can be found in Appendix C-2.  The authors reported a 
significant decrease in SBP, DBP, SVR and SVRI five minutes after induction in group 
P.  The authors also reported a significant decrease in cortisol levels in group E and a 
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significant increase in cortisol levels in group P during weaning from CPB.  The authors 
further determined that etomidate provided more stable hemodynamics than propofol (p < 
0.05). 
 Critical appraisal of this study can be found in Appendix D-2.  The study 
addressed a clearly focused issue.  The assignment of patients to treatments was 
randomized by a computer and performed as a component of the registration process 
prior to the procedure in an outpatient department.  All patients who entered the trial were 
accounted for.  While the assignment to treatment was randomized, the article does not 
report on who, if anyone, was blinded.  The groups were similar at the start of the trial 
and were treated equally, with the exception of the experimental intervention.  The 
treatment effect was not discussed.  The results of the study can be applied to the local 
population.  All clinically important outcomes were considered.  No harmful effects were 
attributed to the study intervention.  Based upon their findings, the authors concluded that 
etomidate provided more stable hemodynamics during induction when compared with 
propofol and that etomidate can be used safely for induction of anesthesia for CABG on 
CPB in patients with good left ventricular function.  The authors further concluded that 
serious decreases in serum cortisol levels produced by etomidate do not last more than 24 
hours. 
 The study performed by Kaushal, Vatal, and Pathak (2015) (Appendix B-3) was a 
prospective, randomized study to compare induction with etomidate and propofol in 
cardiac surgeries.  All patients were undergoing CABG, mitral valve replacement 
(MVR), or aortic valve replacement (AVR) on CPB.  Sixty patients were randomly 
assigned to two groups.  Patients assigned to group I received 2 mg/kg of propofol as the 
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IV induction agent. Patients in group II received 0.2 mg/kg of etomidate as the IV 
induction agent.  All patients received similar doses of glycopyrrolate, midazolam, 
ranitidine, ondansetron, and fentanyl within the same time frame prior to and during the 
induction process.  All patients were monitored using the same invasive and non-invasive 
monitoring modalities.  Data points were recorded for the same hemodynamic parameters 
and cortisol levels at the same time intervals respectively for all patients. 
 The statistical analysis program utilized by the authors was not reported.  Data 
were compiled and summarized by reporting the percentage or range as appropriate for 
the particular data point.  Baseline categorical between-group variables were compared 
using Fisher’s exact test.  Baseline between-group continuous variables were compared 
using Student’s t-test.  Between-group hemodynamic variables were compared using 
Student’s t-test for independent variables.  Between-group comparison of cortisol data 
was performed using the Wilcoxon Rank Sum test.  The authors identified a value of p < 
0.05 as a significant finding.  Outcome measures can be found in Appendix C-3.  The 
authors reported a significant decrease in SBP, DBP, MAP, CO, and CI after induction, 
after intubation, and five minutes post-intubation in group I.  After intubation, SVR 
continued to decrease in group I while it increased above baseline in group II.  The 
authors further reported that serum cortisol decreased significantly in group II while 
increasing significantly in group I.  Serum cortisol in both groups returned to baseline 
levels 24 hours post-operatively (p < 0.001). 
 Critical appraisal of this study can be found in Appendix D-3.  The trial addressed 
a clearly focused issue.  The assignment of patients to treatment was randomized.  All 
patients who entered the trial were accounted for.  The authors reported that 
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randomization was performed by opening a sealed envelope containing the group 
assignment immediately prior to entering the operating room.  The degree to which 
patients, health workers, and study personnel were blind to treatment was not specifically 
addressed.  The methods used to assign particular patients to a particular group were not 
discussed.  Upon opening the envelope, the anesthesia provider would be aware which 
medication would be administered to the patient; however they would have not had any 
forewarning.  The groups were similar at the start of the trial and were treated equally 
with the exception of the experimental intervention.  The treatment effect was not 
discussed.  The results can be applied to the local population.  All clinically important 
outcomes were considered.  No harmful or adverse outcomes were reported.  The authors 
concluded that etomidate provided a more stable hemodynamic profile during the 
induction of anesthesia for patients with poor LV function when compared with propofol 
and that any observed fluctuation in cortisol levels did not result in untoward effects.  
Based upon their findings the authors determined that etomidate can be used safely for 
induction of anesthesia for CABG, MVR, or AVR procedures on CPB in patients with 
poor left ventricular function. 
 A study performed by Shivanna et al. (2015) (Appendix B-4) was a prospective, 
double blind, randomized comparative study to evaluate the hemodynamic effects of 
etomidate in comparison to that of propofol during induction of general anesthesia.  All 
patients were undergoing CABG on CPB.  Forty patients were randomly assigned to two 
groups.  Induction was carried out using an infusion of the assigned medication rather 
than a single bolus dose.  Patients in group P received 0.5 mg/kg/min of propofol as the 
IV induction agent.  Patients in group E received 0.05 mg/kg/min of etomidate as the  IV 
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induction agent.  All patients received similar doses of morphine, promethazine, 
midazolam, fentanyl, and rocuronium within the same time frame prior to or during the 
induction process.  All patients were monitored using the same invasive and non-invasive 
monitoring modalities.  Anesthesia was maintained using sevoflurane in all patients.  
Hemodynamic fluctuations were treated utilizing the same parameters and same 
interventions for all patients.  Data points were recorded for the same hemodynamic 
parameters at the same time intervals in all patients.  
 Statistical analysis was performed using the SPSS, STATA, Med Calc, and Systat 
software platforms.  Patient characteristics were examined using the Chi-square test.  
Between-group comparison was performed using the unpaired t-test.  The authors 
delineated three different levels of significance.  A p-value of 0.05-0.10 was categorized 
as having “suggestive significance”.  A p-value of 0.01-0.05 was categorized as 
“moderately significant”.  A p-value <0.01was categorized as “strongly significant”.  The 
authors performed a power analysis of previous studies to determine that a sample size of 
20 patients per group was required to achieve a power of 80% and a 0.05 for detection of 
the desired hemodynamic changes.  Outcome measures can be found in Appendix C-4.  
The authors reported that MAP decreased in group P more than group E; however the 
difference was not statistically significant.  The authors reported that SVR decreased in 
group P in a moderately significant manner (p=0.022).  The authors further reported that 
after intubation, SVR increased in both groups, with the patients in group E 
demonstrating a statistically significant larger increase than group P (p=0.003). 
 Critical appraisal of this article can be found in Appendix D-4.  The study 
addressed a clearly focused issue.  The assignment of patients was randomized.  All 
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patients who entered the study were accounted for.  Participants were blinded to the 
treatment.  The groups were similar at the start of the trial.  The groups were treated 
equally, with the exception of the experimental intervention.  The treatment effect was 
not discussed.  The results can be applied to the local population.  All clinically important 
outcomes were considered.  No harmful or untoward events were reported.  Based upon 
their findings, the authors concluded that propofol produced a greater reduction in 
contractility, arterial blood pressure, and afterload when compared with etomidate when 
used as an induction agent in patients with coronary artery disease.  The authors further 
concluded that etomidate was less effective than propofol in preventing a patient’s stress 
response to intubation. 
 A study performed by Kamath, Kamath and Patla (2016) (Appendix B-5) was a 
prospective, randomized study to compare propofol with etomidate with respect to 
hemodynamic stability during induction of anesthesia for open cardiac surgical 
procedures.  All study participants were undergoing elective cardiac surgical procedures, 
which included CABG, MVR, and AVR.  Sixty patients were randomly assigned to two 
groups.  Group A received 1.5 mg/kg of propofol as the IV induction agent.  Group B 
received 0.2 mg/kg of etomidate as the IV induction agent.  All patients received similar 
actual or weight-based doses of ranitidine, diazepam, fentanyl, midazolam, and 
rocuronium prior to or during the induction process.  After the induction agents and all 
other adjuncts were administered, all patients were ventilated with 100% oxygen and 1% 
sevoflurane for three minutes prior to intubation.  All patients were monitored using 
identical invasive and non-invasive monitoring modalities.  Data points were collected 
for the same hemodynamic parameters at the same time intervals for all patients. 
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 Statistical analysis was performed utilizing the SPSS software platform.  Baseline 
values were compared using the independent Student’s t-test.  Continuous variables were 
compared using the independent Student’s t-test.  The authors identified a p-value of < 
0.05 as a significant finding.  Outcome measures can be found in Appendix C-5.  The 
authors reported a significant decrease in SBP, MAP, CO and CI after induction in group 
A.  The authors reported a significant increase in DBP, CO and CI after intubation in 
group A.  The authors reported a significant increase in MAP, CVP and PCWP five 
minutes after intubation in group A.  No significant changes were noted in group B for 
any data point at any time. 
 Critical appraisal for this article can be found in Appendix D-5.  The article 
addressed a clearly focused issue.  The assignment of patients was randomized using 
closed envelope technique.  All patients who entered the trial were properly accounted 
for.  It was not clear from the article whether patients, health care workers, or study 
personnel were blind to treatment.  Groups were similar at the start of the trial.  All 
participants were treated equally, with the exception of the experimental intervention.  
Treatment effect was not discussed.  The results can be applied to the local population.  
All clinically important outcomes were considered.  No harmful or untoward effects were 
reported.  Based upon their findings, the authors concluded that etomidate provides a 
more favorable hemodynamic profile when compared with propofol when used for 
induction of anesthesia in cardiac surgical procedures.   
 A study performed by Soleimani et al. (2017) (Appendix B-6) was a double-blind, 
randomized clinical study to compare the hemodynamic responses to propofol, etomidate, 
and diazepam following anesthesia induction, laryngoscopy, and intubation in patients 
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with low ejection fraction.  While this study investigated a medication outside the scope 
of this paper (diazepam), the authors reported data specifically comparing the 
hemodynamic responses to propofol and etomidate, which is directly applicable and 
meets the inclusion criteria.  All study participants were undergoing elective CABG with 
CPB.  One hundred fifty patients were randomly assigned to three equal groups.  Patients 
in group A received 1.5 mg/kg of propofol as the IV induction agent.  Patients in group B 
received 0.2 mg/kg of etomidate as the IV induction agent.  Patients in group C received 
0.3 mg/kg of diazepam as the IV induction agent.  All patients received identical weight-
based doses of midazolam, fentanyl, and succinylcholine during the induction process.  
All patients were monitored utilizing the same invasive and non-invasive monitoring 
modalities.  Data points were collected for the same hemodynamic parameters at the 
same time intervals for all patients.   
 Statistical analysis was performed utilizing the SPSS software platform.  Normal 
distribution of data determination was performed using the Kolmogorov-Smirnov test.  
Quantitative variable analysis was performed using ANOVA and the Bonferroni test.  
The authors identified a p-value < 0.05 as a significant finding.  Outcome measures can 
be found in Appendix C-6.  The authors reported a significant decrease in SBP, DBP, and 
MAP in groups A, B, and C one minute after induction and before laryngoscopy, with the 
reductions in group C being to a lesser degree than groups A and B.  These measurements 
returned to near baseline in groups B and C while remaining significantly reduced in 
group A one minute after laryngoscopy.  The authors reported a significant decrease in 
mean HR one minute after induction in groups A and B, which did not occur in group C.  
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The authors reported that a significantly larger percentage of patients in group A required 
rescue administration of ephedrine when compared with groups B and C. 
 Critical appraisal for this article can be found in Appendix D-6.  The study 
addressed a clearly focused issue.  The assignment of patients to treatments was 
randomized using the sealed envelope technique.  Allocation to a particular group was 
performed based upon a numbers list that was computer-generated by a nurse who was 
unaware of the study groups.  All patients who entered the trial were accounted for at its 
conclusion.  All participants, including the anesthesia provider of record, were blinded to 
the treatment.  To ensure patient safety, medications were prepared by a qualified 
anesthesia provider who was not involved in the study.  Each of the study medications 
was prepared in an equal volume and syringes were covered with tape to conceal any 
identifying characteristics of the medication contained within.  The groups were similar 
at the start of the trial and were treated equally, with the exception of the experimental 
intervention.  Treatment effect was not discussed.  The results can be applied to the local 
population.  Diazepam is not traditionally used as an IV induction agent.  The data 
reported comparing propofol and etomidate are directly applicable to this paper.  All 
clinically relevant outcomes were considered.  No harmful or untoward events were 
reported.  The authors’ conclusion was that diazepam provided more favorable 
hemodynamics than propofol and etomidate.  The extraction of data comparing propofol 
and etomidate demonstrated that propofol results in a greater decrease in SBP, DBP, and 
MAP when compared to etomidate and the decrease continues for a greater length of time 
in patients receiving propofol.  This is consistent with the substantially greater need for 
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rescue administration of ephedrine for patients receiving propofol (28%) compared with 
those receiving etomidate (4%). 
 A study performed by Mala and Narmada (2017) (Appendix B-7) was a 
prospective, randomized study to compare the hemodynamic profile and hormonal 
alteration between etomidate and propofol following induction of anesthesia.  All patients 
included in this study were undergoing elective CABG with CPB.  Thirty patients were 
randomly assigned to two equal groups.  Patients in the propofol group received 2 mg/kg 
of propofol as the IV induction agent.  Patients in the etomidate groups received 0.2 
mg/kg as the IV induction agent.  All patients were monitored utilizing the same invasive 
and non-invasive monitoring modalities.  Data were collected for the same hemodynamic 
parameters at the same time intervals for all patients. 
 The authors reported that statistical analysis was performed, however the methods 
used were not reported.  The authors identified a p-value < 0.05 as a significant finding.  
Outcome measures can be found in Appendix C-7.  The authors reported a significant 
reduction in SBP compared to baseline in the propofol group after induction, which was 
much lower five minutes after intubation.  The authors reported a significant decrease in 
CI from baseline in the propofol group when measured two and three minutes following 
induction.  The authors reported a 50% decrease in serum cortisol at the initiation of CPB 
in the etomidate group, while serum cortisol in the propofol group was nearly double the 
baseline level. 
 Critical appraisal of this article can be found in Appendix D-7.  The trial 
addressed a clearly focused issue.  The authors reported that assignment of patients to 
treatments was randomized; however, the randomization method was not provided.  The 
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authors reported that the patients were randomly assigned to two groups, but there was no 
further discussion as to the disposition of these patients.  The groups were similar at the 
start of the trial.  The treatment regimen outside of the experimental intervention was not 
discussed.  The authors neither stated that the regimen was the same across all patients, 
nor stated that it was different.  Treatment effect was not discussed.  The results can be 
applied to the local population.  All clinically important outcomes were considered.  No 
harmful or untoward events were reported.  Based upon their findings, the authors 
concluded that induction with etomidate provided more hemodynamic stability when 
compared with propofol.  The authors reported that etomidate caused a transient 
reduction in serum cortisol which normalizes within two hours.  The authors conclusory 
statement was that etomidate can therefore be used safely for induction of anesthesia in 
patients with good left ventricular function for CABG with CPB. 
 A study performed by Meena et al. (2017) (Appendix B-8) was a prospective 
randomized study to compare the effects of etomidate and propofol on hemodynamic and 
serum cortisol levels.  All patients included in the study were undergoing elective CABG 
with CPB.  Sixty patients were randomized into two equal groups.  Patients in group A 
received 0.3 mg/kg of etomidate as their IV induction agent.  Patients in group B received 
2.0 mg/kg of propofol as their IV induction agent.  All patients received similar weight-
based doses of morphine, promethazine, fentanyl and rocuronium prior to or during the 
induction process at the same time intervals.  All patients were monitored using the same 
invasive and non-invasive monitoring modalities.  Data were collected for the same 
hemodynamic parameters and serum levels at the same time intervals for all patients. 
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 Statistical analysis was performed utilizing the SPSS software platform.  
Quantitative measurements were reported with means and standard deviations.  The 
unpaired t-test was used to analyze the between-group difference between the means.  
The paired t-test was used to analyze the within-group difference between the means.  
The authors reported qualitative data, which only includes patient age, as a number and 
percentage.  The chi square test was used to analyze the differences in qualitative data.  
The authors maintained a significance level of 95% for all analyses.  Outcome measures 
can be found in Appendix C-8.  The authors reported a significant decrease in SBP, DBP, 
SVR and SVRI in group B after induction.  The authors reported a significant increase in 
HR and SBP after intubation in group A.  The authors reported a significant decrease in 
serum cortisol when coming off bypass in group A, with a significant increase in group 
B. 
 Critical analysis of this article can be found in Appendix D-8.  The trial addressed 
a clearly focused issue.  The assignment of patients to treatments was randomized.  
Randomization was performed using the chit-in-box method.  All patients were 
accounted for at the trial’s conclusion.  The authors did not report on the blinding of any 
participants.  The groups were similar at the start of the trial.  While the calculated 
distribution of patients according to sex was not statistically significant, 85% of the 
patients enrolled in the study were male.  In group A, there were only two females, while 
in group B, there were only seven females.  The authors reported that there were no 
statistically significant differences between groups; however, the within-group gender 
distribution is noteworthy.  The groups were treated equally, with the exception of the 
experimental intervention.  Treatment effect was not discussed.  The results can be 
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applied to the local population.  All clinically important outcomes were considered.  The 
authors reported four instances of pain with injection, one instance of severe hypotension, 
and two instances of bradycardia in group B, and 2 instances of myoclonus in group A.  
Based upon their findings, the authors concluded that etomidate prevented the surge in 
serum cortisol at the institution of CPB that is seen when propofol is used and that 
etomidate produced a more stable hemodynamic profile than propofol during induction 
without blunting the sympathetic stimulation to laryngoscopy. 
 A study performed by Hannam et al. (2019) (Appendix B-9) was a randomized 
controlled superiority trial to test the hypothesis that etomidate is superior to propofol for 
induction of anesthesia in relation to hemodynamic stability over the first 10 minutes 
after induction in patients undergoing cardiac surgery.  All patients enrolled in the study 
were undergoing elective CABG, valve surgery, CABG/valve surgery, and thoracic aorta 
surgery.  One hundred fifty patients were enrolled in the study, which was conducted in 
two phases.  Initially, 156 patients were randomized.  After randomization, six patients 
were not included in the final results.  The authors reported that four patients were 
excluded just prior to surgery, while two were not included due to corrupted electronic 
medical records.  Each phase included two patient groups, each of which were 
randomized to receive either propofol or etomidate as the IV induction agent.  
Randomization was completed prior to the start of phase I, resulting in sample size 
variation between and within phases.  The first phase was open-label, during which the 
anesthesia provider was not blinded to the treatment drug (n=76; propofol = 40, 
etomidate =3 6).  The second phase was closed-label, during which all clinical staff were 
blinded (n=74; propofol = 35, etomidate = 39).  All patients received midazolam, 
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fentanyl, and a non-specific non-depolarizing neuromuscular blocking medication prior 
to or during the induction process.  The doses for these medications, and choice of non-
depolarizing neuromuscular blocking medication, were not standardized and left to the 
discretion of the anesthesia provider.  Anesthesia was induced using non-standardized 
doses of the IV induction agent.  Anesthesia providers were permitted to titrate the 
administration at their discretion to achieve loss of consciousness.  All patients were 
monitored utilizing the same invasive and non-invasive monitoring modalities.  Data 
were collected for the same hemodynamic parameters at the same time intervals for all 
patients. 
 The authors reported that their primary endpoint for the purpose of statistical 
analysis was determining the total use of vasopressor medications within the first 10 
minutes after induction of anesthesia.  This data was reported as either requiring 
vasopressor medication or not requiring vasopressor medication and between group 
comparisons were made using logistical regression, summarized as odds ratios with 95% 
confidence intervals. The authors reported that stratification was performed to control for 
variations in anesthetist behavior, open versus closed-label phases, and baseline MAP.  
Outcome measures can be found in Appendix C-9.  Based upon their findings, the authors 
concluded that propofol produced a 34% greater reduction in MAP when compared with 
etomidate and that etomidate provided a superior hemodynamic profile to propofol. 
 Critical appraisal can be found in Appendix D-9.  The trial focused on a clearly 
focused issue.  The assignment of patients was randomized.  All patients who were 
entered into the trial were accounted for at the end of the study.  The study was 
performed in two phases.  Phase I was conducted in an open-label format.  Phase II was 
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conducted in a closed-label format during which all clinical and study staff were blinded 
to the induction drug.  Between group makeup was similar between groups.  Within-
group makeup was skewed substantially toward male patients.  The groups were treated 
equally insofar as they received the same medication regimen, with the exception of the 
treatment intervention.  Dosing of the IV induction agent, as well as the other adjunct 
medications, varied at the discretion of the individual anesthetist.  The formulation of 
etomidate was changed for phase II.  To further blind the anesthesia provider to the 
treatment medication, a lipid-based emulsion formulation of etomidate was utilized, 
rendering it visually indistinguishable from propofol.  The treatment effect was not 
discussed.  The results can be applied to the local population.  All clinically important 
outcomes were considered.  There were no harmful or untoward events reported.  The 
authors did comment on the safety of their approach.  They reported that when both 
induction agents were visually indistinguishable, with a color and consistency 
traditionally associated with propofol, anesthetists treated both medications as though 
they were propofol.  Since the lipid-based etomidate emulsion was not diluted so that the 
per milliliter concentration for the appropriate weight-based dose range was similar to 
propofol, this led to a more than three-fold increase in actual dose of etomidate 
administered during the blinded phase.  The authors admitted that this method of blinding 
caused a deviation from practice in the blinded phase that could have put patients at risk 







 The cross-study analysis can be found in Appendix E.  A single study was found 
(Basagan et al., 2010) comparing propofol to ketamine.  All of the remaining studies 
(Hannam et al., 2019; Kamath et al., 2016; Kaushal et al., 2015; Mala & Narmada, 2017; 
Meena et al., 2017; Pandey et al., 2012; Shivanna et al., 2015; Soleimani et al., 2017) 
compared propofol to etomidate and all investigated and compared the hemodynamic 
changes associated with the administration of each medication.  Three of the studies 
(Kaushal et al., 2015; Meena et al., 2017; Pandey et al., 2012) investigated cortisol 
response to propofol and etomidate in addition to the hemodynamic changes.   
Dosing of each medication was generally consistent across studies.  Bolus doses 
of propofol were used at 2.0 mg/kg (Kaushal et al., 2015; Meena et al., 2017; Pandey et 
al., 2012; Soleimani et al., 2017) and 1.5 mg/kg (Kamath et al., 2016; Mala & Narmada, 
2017).  An infusion of 0.5 mg/kg/min of propofol was used in study 4 (Shivanna et al., 
2015).  Propofol was dosed at the anesthesia provider’s discretion in study 9 (Hannam et 
al., 2019).  Bolus doses of etomidate were used at 0.2 mg/kg (Kamath et al., 2016; 
Kaushal et al., 2015; Mala & Narmada, 2017; Meena et al., 2017; Pandey et al., 2012) 
and 0.3 mg/kg (Soleimani et al., 2017).  An infusion of 0.05 mg/kg/min of etomidate was 
used in study 4 (Shivanna et al., 2015).  Etomidate was dosed at the anesthesia provider’s 
discretion in study 9 (Hannam et al., 2019).  A bolus dose of ketamine was used at 0.2 
mg/kg in study 1 (Basagan et al., 2010). 
The administration of propofol was generally associated with a clinically 
significant reduction in hemodynamic parameters after induction.  The administration of 
propofol was associated with a reduction in SBP in all studies.  Diastolic blood pressure 
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was reduced in studies two, three, six and eight (Kaushal et al., 2015; Mala & Narmada, 
2017; Pandey et al., 2012; Soleimani et al., 2017).  Mean arterial pressure was reduced in 
studies one, three, four, five, six and nine (Basagan et al., 2010; Hannam et al., 2019; 
Kamath et al., 2016; Kaushal et al., 2015; Mala & Narmada, 2017; Shivanna et al., 2015).  
Systemic vascular resistance was reduced in studies one, two, three, and eight (Basagan 
et al, 2010; Kaushal et al., 2015; Pandey et al., 2012; Soleimani et al., 2017).  Study six 
(Mala & Narmada, 2017) reported that a greater number of patients receiving propofol 
required rescue administration of ephedrine when compared with etomidate.  The 
administration of etomidate was associated with an increase in DBP, CO and CI (Mala & 
Narmada, 2017), as well as HR and SBP (Soleimani et al., 2017) after intubation.  
Etomidate was associated with a decreased cortisol level (Kaushal et al., 2015; Meena et 
al., 2017; Pandey et al., 2012), while propofol was associated with an increased cortisol 
level (Kaushal et al., 2015; Meena et al., 2017; Pandey et al., 2012).  No statistically 
significant changes in hemodynamic parameters were associated with the administration 
of ketamine.  Alterations in cortisol in response to ketamine were not studied. 
Creation of Decision Tree 
Based upon the information collected during the cross-study analysis, a decision 
tree (Figure 4, p. 55) was constructed to guide the anesthesia practitioner to the most 
appropriate choice of IV anesthetic for a particular patient.  First, any known allergy, 
hypersensitivity, comorbid condition, or known genetic condition that precludes the use 
of a particular medication should be considered.  Next, the determination must be made 
as to whether the patient is in a moribund state or experiencing an emergency situation.  
In these situations, it may be necessary for the anesthesia provider to make risk versus 
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benefit judgments based upon their experience and to choose the medication that he/she 
believes provides the greatest likelihood of causing the least harm.  Finally, decision 
points would be based upon the known pathophysiology of various structural heart 
conditions and the IV anesthetic whose hemodynamic effects profile provides the 





Figure 4. Decision tree  
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Utilization of the Decision Tree 
After a thorough review of the patient’s medical record and pre-admission testing, 
the anesthesia provider performing the induction should perform a detailed pre-anesthesia 
assessment and physical exam.  Based upon those findings, the anesthesia provider 
should refer to the decision tree to select the IV induction agent best suited for the 
patient’s condition.  It’s understood that an emergency situation may preclude a thorough 
medical record review and/or pre-anesthesia assessment.  In this instance, every attempt 
should be made to identify the patient’s known medication allergies and pertinent 
medical history by any means possible.  The decision tree is not a substitute for clinical 
judgment.  The anesthesia provider should not administer any medication to a patient 
they feel would be harmful, regardless of the recommendation obtained from the decision 
tree.  Personal preference, facility custom, budgetary, or other non-medical motivations 
are not a substitute for evidence-based practice, and should not be used as an excuse to 
ignore the decision tree. 
The decision tree should be read from top to bottom.  A key is provided for 
reference.  Items in blue boxes are considered decision points.  Items in red boxes should 
prompt the anesthesia provider to stop and consider eliminating the applicable medication 
as an option for the patient.  Items in orange boxes are based upon recommendations 
from research outside the scope of this project.  Items in green boxes are the best choice 
based upon the research performed during this project.  
First, any medication for which a patient has a known allergy or hypersensitivity 
should not be used.  This includes medical or genetic conditions for which administration 
of the particular medication could cause harmful side effects.  Next, the anesthesia 
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provider should consider whether or not the patient is suffering from an emergency 
situation rendering them hemodynamically unstable.  Ketamine has been recognized as 
the best choice in hemodynamically unstable emergency situations by international 
organizations (Morris et al., 2009).  Next, the anesthesia provider should consider 
whether or not the patient suffers from coronary artery disease.  A “yes” answer 
eliminates ketamine as a medication choice and the anesthesia provider should continue 
down the decision tree without considering ketamine.  A “no” answer permits the 
anesthesia provider to continue down the decision tree maintaining ketamine in their 
repertoire.  Next, the anesthesia provider should consider heart valve findings from the 
pre-operative echocardiogram.  The presence of stenotic or regurgitant valve lesions will 
guide the direction of travel down the decision tree where it splits into two columns.  The 
choice of IV induction agent most appropriate for the patient is based upon the 
recommendation in the green box.  Where multiple options are listed, clinical judgment 
should guide the selection.  There is no evidence to support the selection of ketamine or 
etomidate over the other.  




Summary and Conclusions 
Anesthesia providers have multiple IV anesthetic medications at their disposal 
from which to choose when selecting the agent best suited for their patients’ 
comorbidities and the proposed surgical procedure (Nagelhout, 2014).  Patients 
presenting for cardiac surgery are likely to bring a plethora of comorbidities affecting end 
organ function.  These patients are high risk, as are the surgeries.  It’s imperative that the 
anesthesia provider facilitate a smooth and stable induction to protect the patient from 
additional physiologic compromise.   
The purpose of this paper was to propose a preliminary, evidence-based decision 
tree to guide in the selection of an appropriate intravenous anesthetic for patients 
undergoing cardiac surgery.  Two theoretical frameworks were utilized to guide this 
project.  The Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) was used to guide the research process.  Information Processing Theory (ITP) 
was implemented to guide development of the decision tree.  A comprehensive literature 
search yielded nine RCTs meeting inclusion criteria (Appendix A).  Data and outcome 
measures were collected from each RCT and summarized in Appendices B and C.  The 
Critical Appraisal Skills Programme (CASP) was applied to each RCT, with results 
summarized in Appendix D.  The cross-study analysis is detailed in appendix E.  The 
literature review and cross-study analysis guided the creation of the decision tree.  The 
decision tree can be found in Figure 4. 
The decision tree first accounts for allergies and hypersensitivities, followed by 
conditions for which the administration of a particular IV anesthetic could cause severe 
or life-threatening consequences notwithstanding the hemodynamic changes.  For 
example, etomidate is contraindicated in patients with porphyrrias (Nagelhout, 2014).  
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Emergency situations must be handled differently than elective cases.  Ketamine is 
generally recognized as a vital medication during emergency situations (Morris et al., 
2009).  The cross-study analysis guided the development of the subsequent steps in the 
decision tree. 
Principal findings of the cross-study analysis include the association of a 
clinically significant reduction in several hemodynamic parameters with propofol when 
compared with ketamine and etomidate.  Ketamine was associated with superior 
maintenance of MAP and SVR.  Across applicable studies, etomidate was associated with 
a more stable hemodynamic profile than propofol.  When comparing data collection 
points across studies comparing propofol to etomidate, results were relatively consistent, 
depending on hemodynamic parameters measured, within-procedure collection intervals, 
and conclusions reported.  Generally, patients receiving propofol experienced a clinically 
significant decline in blood pressure (SBP, DBP and/or MAP) after induction when 
compared with etomidate.  Two studies (Kamath et al., 2016; Meena et al., 2017) 
reported an increased HR and some blood pressure parameter after intubation in patients 
receiving etomidate.  This is consistent with etomidate’s lack of sympathetic blunting and 
customary patient response to intubation.  Kamath et al (2016) also reported increased 
CO and CI after intubation when etomidate was used, which is consistent with the 
physiologic changes seen with a sympathetic discharge during intubation.  Two studies 
(Kaushal et al., 2015; Soleimani et al., 2017) reported a significant decrease in SVR with 
etomidate, although to a lesser degree than propofol.  In studies utilizing cortisol response 
as an outcome measure, etomidate was generally associated with a decrease in cortisol 
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levels while propofol was associated with an increase.  Long-term effects of cortisol 
response were outside the scope of these studies. 
Propofol, etomidate, and ketamine each have their place in the care of cardiac 
surgery patients.  Anesthesia providers can utilize their understanding of the 
pharmacology of IV anesthetics and the pathophysiology of various structural heart 
diseases to guide their decision-making.  In patients with conditions having 
hemodynamic needs at odds with each other (i.e. CAD and aortic stenosis), it may be 
necessary to choose “the lesser of two evils” and select the medication that will generate 
the more easily addressed side effects.  In general, patients presenting with conditions for 
which blood pressure and SVR must be maintained, such as patients with stenotic valve 
pathologies, would benefit from a medication that preserves each, such as etomidate or 
ketamine.  Ketamine should be avoided in patients for which an increased HR and 
myocardial oxygen demand would be detrimental.  Myocardial ischemia during induction 
could ultimately lead to additional myocardial damage.  Etomidate, or carefully titrated 
propofol, would provide the safest induction in these patients.  Propofol’s best use will be 
in patients for which a decrease in SVR is desirable, such as in regurgitant valve 
pathologies.  Ketamine’s best use may be in the case of emergency procedures or in 
patients where preservation of compensatory mechanisms is paramount.  Its 
bronchodilatory effects may also benefit patients with coexisting severe reactive airway 
disease.  
Limitations were identified at various points throughout the completion of this 
project.  One lone study meeting the inclusion criteria was found comparing propofol 
with ketamine.  The findings in this study are consistent with what would be expected 
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based on the pharmacology of each medication and the known physiologic responses.  No 
studies were located comparing etomidate with ketamine during cardiac surgery.  This 
likely dictates that any decision regarding medication selection between the two be 
dependent upon the known indications and contraindications to each medication rather 
than direct evidence demonstrating the benefit of one over the other.  Dosing of 
medications was not consistent across all studies.  Differing bolus doses were seen across 
studies and one study employed infusions rather than boluses.  Another study permitted 
the anesthesia provider to administer the assigned medication by the method and dose of 
their choosing.  This interferes with the ability to demonstrate the safest 
dose/administration procedure yet does establish that the patients’ responses are 
reasonably consistent across protocols. 
The process used to develop this project also presented limitations.  The nature of 
modern evidence-based practice favors the utilization of the most current information.  
Limiting the inclusion criteria to studies performed in the previous ten-year period 
increased the likelihood that data further supporting or disputing the conclusions were 
omitted.  Excluding research published in languages other than English may have had the 
same effect.  The researcher’s lack of experience conducting projects of this nature may 
also have limited the quality of the research and the veracity of its findings or 
recommendations. 





Recommendations and Implications for Advanced Nursing Practice 
            Advanced Practice Registered Nurses (APRN) are perfectly positioned as leaders 
in the healthcare system.  In addition to their extensive education and experience at the 
bedside in the RN role, APRNs are trained to provide comprehensive and compassionate 
care within their area of expertise.  Evidence-based practice is the foundation of nursing 
education at all levels.  Nurses are trained to seek out the best available evidence, 
evaluate that evidence, and implement their findings into clinical practice so as to provide 
their patients the best possible care.  The cumulative benefits of APRN experience, 
education and capability uniquely qualify them to meet the complex needs of their 
patients. 
 Certified Registered Nurse Anesthetists in particular are in a position to lead 
innovation practice improvements.  The rigor of CRNA education, coupled with its 
strong foundation in the sciences, augments the evidence-based, patient-centered nursing 
care all CRNAs learned to provide at the bedside.  Certified Registered Nurse 
Anesthetists are often the sole anesthesia provider, especially in rural areas where 
resources are limited.  As experts in the provision of all modalities of anesthesia care in 
all settings, CRNAs are sought after for their expertise and leadership skills.  They are in 
a unique position to assume a leadership role and champion practice improvements 
through the implementation of evidence-based interventions.   
The utilization of two theoretical frameworks played a pivotal role in realizing the 
benefits of this project.  Most research studies focus on answering a particular question or 
set of questions.  These studies may or may not discuss the manner in which practitioners 
could implement those answers into generalized practice.  The combination of the two 
frameworks used (PRISMA and IPT) not only assisted in finding and processing the 
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available evidence on the research topic, but also served as the foundation for the 
subsequent steps necessary to translate the evidence into practice.  In order for new 
evidence to extend beyond the esoteric and abstract, we must be able to demonstrate the 
mechanism by which it can be used for the betterment of patients.  Understanding the 
decision-making process, especially by healthcare practitioners, is vital to establishing the 
basis for moving research findings from the classroom to the bedside.  It would be 
beneficial for nursing educators and change leaders in the healthcare industry to expand 
their research processes to include decision-making theories as a compulsory component. 
This type of research supports culturally competent care to diverse populations 
and works toward ensuring ethical practice by all caregivers.  Each and every patient 
deserves the highest level of care, backed by the latest evidence, to guide their treatment 
and see them through to the best possible outcome.  Sound decision-making practices 
based on solid evidence, distilled through an interdisciplinary team of expert clinicians 
can achieve those goals.  This project lends some insight into how APRNs in general, and 
CRNAs in particular, can use research to enhance patient care.  They are uniquely 
prepared to lead these efforts.   
Certified registered nurse anesthetists (CRNAs) in particular are positioned to 
lead a team of caregivers from multiple disciplines to see the patient through the surgical 
experience.  Certified Registered Nurse Anesthetists are educated to practice 
independently while providing all types of anesthesia to all patient populations.  Decision 
trees such as the one developed in this project, as well as other decision-making aids, will 
complement the education, experience, and critical-thinking expertise of CRNAs as they 
work to provide the best possible care to their patients.  Nurse anesthesia educational 
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programs are the ideal setting to nurture the thought processes and leadership skills 
needed to increase the ubiquity of evidence-based guidelines and decision trees.  
Beginning in 2025, all graduates of nurse anesthesia educational programs will be 
required to earn a Doctor of Nursing Practice (DNP) for entry into practice (Madsen 
Gombkoto et al., 2014).  Many programs have already transitioned to a DNP curriculum.  
With the DNP program requirement of the completion of a practice improvement project, 
all new CRNAs will launch their career with experience in designing and implementing 
evidence-based practice improvements.  The integration of decision-making processes 
should be a compulsory component of these projects. 
Much work remains to be done to overcome dated attitudes and individual 
comfort zones.  The first step would be to recognize the subject areas with the greatest 
discrepancy between current behavior and best practices.  Further research is needed to 
identify topic areas with the greatest inconsistencies to guide the prioritization of practice 
improvement efforts.  Another area of future research could involve revisiting past 
evidence-based implementation attempts which failed to produce the desired results.  
Incorporating research related to decision-making in healthcare could bridge the gap 
between the practice improvement and its successful implementation with optimal 
results.   
Decision trees such as the one developed during this project can improve practice 
to coincide with the most current research on a particular topic and support consistency 
within an organization.  This effort requires collaboration among all stakeholders and 
across multiple disciplines.  Some changes may necessitate organizational policy 
modifications, or perhaps legislative action.  Focused, professional leadership is 
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necessary to navigate the process.  Certified Registered Nurse Anesthetists are the ideal 
expert providers to utilize their education, experience and position as respected APRNs to 
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Group K (n=15): 
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IV induction agent 
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Received propofol as 
IV induction agent 
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IV, scheduled for 
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procedure 
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Group K patients 
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ketamine. 
 
Group P patients 





induction, one minute 
after induction, one, 
three and ten minutes 
after intubation, one 
minute after incision, 
and one minute after 
sternotomy 
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induction, significant 
decreases in MAP and 
SVR one minute after 
induction in Group P (p 
< 0.01) 
 
No significant changes 
in HR, PAP, PCWP, 




No significant changes 
in ST segment 
deviation from baseline 
between groups 
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SBP (p=0.0005), DBP 
(p=0.0011), SVR 
(p=0.0474), SVRI 
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after intubation in 
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Serum cortisol levels 
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IV induction agent  
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IV induction agent 
 
Randomization 
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Study site not provided 
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ASA class II or III, 
scheduled for elective 




CHF, renal dysfunction 
(creatinine > 2 mg/dl), 




known adrenal or 
endocrine dysfunction, 
or undergoing an 
emergency operation  
All patients: identical 
doses of glycopyrrolate, 
midazolam, ranitidine, 
and ondansetron, same 
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minutes post intubation 
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using infusion of IV 
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before induction, after 
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minutes post induction 
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performed using closed 
envelope technique 
 
Site: Not provided.  
Authors are affiliated 




Sixty adult patients, 
ages 20-60 
 
Excluded: Not provided  
All patients: 
premedicated orally 
with 50 mg ranitidine 
and 10 mg diazepam 
night before surgery  
 
Received fentanyl 5 




Group A: 1.5 mg/kg 
propofol 
 





before induction, after 
induction, after 
intubation, and five 






decrease in SBP, MAP, 




increase in DBP, CO 
and CI (p<0.05) 
 
Five minutes after 
intubation: 
Statistically significant 
increase in MAP, CVP, 
and PCWP in propofol 
(p<0.05)  
 
No significant changes 
in any other parameters 
at these times 
 
Etomidate group: 
No significant changes 







Note: IV-intravenous, SBP-systolic blood pressure, DBP-diastolic blood pressure, MAP-mean arterial pressure, CO-cardiac output, CI-cardiac index, SVR-





Soleimani, A., Heidari, N., Habibi, M. R., Kiabi, F. H., Khademloo, M., Zeydi, A. E., & Sohrabi, F. B. (2017). Comparing 
hemodynamic responses to diazepam, propofol and etomidate during anesthesia induction in patients with left ventricular dysfunction 
undergoing coronary artery bypass graft surgery: A double-blind, randomized clinical trial. Medical Archives, 71(3), 198-203. 
https://doi.org/10.5455/medarh.2017.71.198-203 
Purpose Project Design Site, Sample Method Results Limitations 
To compare the 
hemodynamic 
responses to propofol, 
etomidate and diazepam 
following anesthesia 
induction, laryngoscopy 
and intubation in 
CABG surgery patients 




study of 150 patients 
scheduled for elective 
CABG with CPB, 
randomly allocated into 
three groups of 50 
 
Group A: Received 
propofol as IV 
induction agent  
 
Group B: Received 
etomidate as IV 
induction agent 
 
Group C: Received 




performed using closed 
envelope technique 
 
Site: Cardiac surgery 
unit and open heart 




of Medical Sciences, 
Sari, Iran 
 
150 adult patients with 
CAD and left 
ventricular dysfunction 
(EF ≤ 35%), and stable 
hemodynamics 
 
Excluded: Patients with 









Premedicated with 2 
mcg/kg fentanyl and 




induction to facilitate 
intubation 
 
Group A (n=50):  
1.5 mg/kg propofol 
 
Group B (n=50):  
0.2 mg/kg etomidate 
 
Group C (n=50):  




before induction, before 
larygoscopy, one and 
five minutes post 
induction 
Statistically significant 
decrease in SBP, DBP 
and MAP in all three 
groups one minute after 
induction (p<0.001).  
Decrease remained for 
other measurements in 
propofol group 
(p<0.001), with 
recovery to near 





of patients in the 
propofol group required 
rescue administration of 
ephedrine compared 




Dosages per kilogram 
of body weight may be 
unequally distributed 
between groups, and be 




Note: IV-intravenous, CAD-coronary artery disease, EF=ejection fraction, SBP-systolic blood pressure, DBP-diastolic blood pressure, MAP-mean arterial 





Mala, R., & Narmada, S. (2017). Prospective randomised study comparing the haemodynamic and endocrine response to induction 
with etomidate and propofol in patients undergoing cardiac surgery on cardiopulmonary bypass. Indian Journal of Applied Research, 
7(10), 145-146. Retrieved from https://www.worldwidejournals.com/indian-journal-of-applied-research 
(IJAR)/fileview/October_2017_1506777489__54.pdf 
Purpose Project Design Site, Sample Method Results Limitations 
To compare the 
hemodynamic profile 
and the hormonal 
alteration between 
etomidate and propofol 
following induction in 
cardiac surgery, 
particularly in patients 
undergoing coronary 




study of 30 patients 
scheduled for elective 
CABG with CPB, 
randomly allocated into 
two groups of 15 
 
Propofol Group (n=15): 
Received 2 mg/kg 
propofol as IV 
induction agent  
 
Etomidate Group 
(n=15): Received 0.2 




performed using closed 
envelope technique 
 
Site: Not Provided 
 
Sample: 
30 adult patients (ages 
18-60), ASA II and III, 
Mallampati I and II, 
with normal LV 
function  
 









(creatinine > 2.0 
mg.dL), difficult 
airway, poor lung 






before induction, at 
one, two and three 
minutes after induction, 
and at 1 and five 
minutes after intubation 
 
Statistically significant 
decrease in SBP from 
baseline after induction, 
much lower 5 minutes 





decrease in CI from 
baseline, two, and three 
minutes following 




Serum cortisol 50% of 
baseline at initiation of 
CPB in etomidate 
group, almost double 




Dosages per kilogram 
of body weight may be 
unequally distributed 
between groups, and be 




Note: IV-intravenous, CAD-coronary artery disease, EF=ejection fraction, SBP-systolic blood pressure, DBP-diastolic blood pressure, MAP-mean arterial 




Meena, R., Sharma, R. S., Ranawat, P., Saiyed, A., & Verma, I. (2017). Comparison of hemodynamic and serum cortisol levels in 
response to anesthetic induction with etomidate or propofol in patients undergoing CABG surgery. Indian Journal of Clinical 
Anaesthesia, 4(3), 345-351. https://doi.org/10.18231/2394-4994.2017.0071 
Purpose Project Design Site, Sample Method Results Limitations 
To compare the effects 
of induction agents 
etomidate and propofol 
on hemodynamic and 
serum cortisol levels in 
patients undergoing 
coronary artery bypass 




study of 60 patients 
scheduled for elective 
CABG with CPB, 
randomly allocated into 
two groups of 15 
 
Group A (n=30): 
Received etomidate 0.3 
mg/kg as IV induction 
agent 
 
Group B (n=30): 
Received propofol 2.0 




performed by “chit in 
the box” method 
 
Site: Department of 
Anesthesiology, S.M.S. 
hospital and attached 
group of hospitals, 
Jaipur, Rajasthan, India 
 
Sample: 
60 adult patients (ages 
25-60), ASA II and III, 
with triple vessel 
disease and LVEF 
<45%, presenting for 
elective CABG  
 






existing arrhythmias, on 
mechanical ventilation, 





NPO x eight hours 
 
Morphine 0.1 mg/kg IM 
and promethazine 0.5 
mg /kg IM 30 minutes 
prior to induction 
 
Fentanyl 4 mcg/kg, then 
baseline parameters 
(HR, SBP, DBP, MAP, 
CVP, PCWP, CO, CI, 
SVR, SVRI, PVR, 
PVRI) were recorded 
over ten minutes with 
pre-oxygenation, after 





cortisol level recorded 2 
minutes after induction 
and after intubation. 
 
Cortisol level: 
     Group A: significant 
decrease (up to 60%) 
from baseline coming 
off bypass (p=0.0036), 
significant increase 
from baseline 24 hours 
post op 
     Group B: Large, but 
statistically 
insignificant increase 
(up to double) coming 
off bypass, also 
significant increase 24 
hours post op 
 
Hemodynamics: 
Significant decrease in 




induction in group B 
 
Large, but statistically 
insignificant increase in 
Small sample size 
89 
 
HR and SBP after 
intubation in group A  
 
Note: CABG-coronary artery bypass graft, CPB-cardiopulmonary bypass, IV-intravenous, , ASA-American Society of Anesthesiologists, LVEF-left ventricular 
ejection fraction, NPO-nothing per os, IM-intramuscular, HR-heart rate, SBP-systolic blood pressure, DBP-diastolic blood pressure, MAP-mean arterial pressure, 
CVP-central venous pressure, PCWP-pulmonary capillary wedge pressure, CO-cardiac output, CI-cardiac index, SVR-systemic vascular resistance, SVRI-




Hannam, J. A., Mitchell, S. J., Cumin, D., Frampton, C., Merry, A. F., Moore, M. R., & Kruger, C. J. (2019). Haemodynamic profiles 
of etomidate vs propofol for induction of anaesthesia: A randomised controlled trial in patients undergoing cardiac surgery. British 
Journal of Anaesthesia, 122(2), 198-205. https://doi.org/10.1016/j.bja.2018.09.027 
Purpose Project Design Site, Sample Method Results Limitations 
To test the hypothesis 
that etomidate is 
superior to propofol for 
induction of anesthesia 
in relation to 
hemodynamic stability 
over the first 10 
minutes after induction, 
in patients undergoing 
cardiac surgery 
Randomized, controlled 
superiority trial with 
open-label (unblended) 
and blinded phases. 
 
Phase I (n=76): open 








Phase II (n=74): closed-






Group (n=39)  
 
 
Site: Green Lane 
Cardiothoracic Surgery 




150 adult patients (ages 
18-60), ASA II-IV, 
undergoing elective 
CABG, valve surgery, 
combination 
CABG/valve surgery, 









midazolam and fentanyl 
at the anesthetists’ 
discretion, with non-
standardized doses 
chosen by the 
anesthetist.  Induction 
was accomplished with 
titration of the allocated 
medication to loss of 
responsiveness to 
verbal stimuli.  The 
remainder of the 
anesthetic appeared to 
be standardized. 
 
MAP recorded every 30 
seconds.  Primary 
endpoint was area 
under the baseline MAP 
over the first 10 
minutes after induction 
 
34% greater reduction 
in MAP with propofol 
than with etomidate 




Unequal numbers of 
study subjects between 
phases and between 
anesthetics within each 
phase 
 
Lack of standardized 




related to anesthesia 
provider decision-
making and practice 










Basagan-Mogol, E., Goren, S., Korfali, G., Turker, G., & Kaya, F. N. (2010). Induction of anesthesia in coronary artery bypass graft 
surgery: The hemodynamic and analgesic effects of ketamine. Clinics, 65(2), 133-138. https://doi.org/10.1590/S1807 
59322010000200003 
 Propofol Etomidate Ketamine 
Heart Rate 0  0 
Systolic Blood Pressure NR  NR 
Diastolic Blood Pressure NR  NR 
Mean Arterial Pressure ↓  0 
Cardiac Output 0  0 
Cardiac Index 0  0 
SVR ↓  0 
Endocrine Response NR  NR 
 
Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify 




Pandey, A. K., Makhija, N., Chauhan, S., Das, S., Kiran, U., Bisoi, A. K., & Lakshmy, R. (2012). The effects of etomidate and 
propofol induction on hemodynamic and endocrine response in patients undergoing coronary artery bypass graft surgery on 
cardiopulmonary bypass. World Journal of Cardiovascular Surgery, 2(3), 48-53. https://doi.org/10.4236/wjcs.2012.2301 
 Propofol Etomidate Ketamine 
Heart Rate 0 0  
Systolic Blood Pressure ↓ 0  
Diastolic Blood Pressure ↓ 0  
Mean Arterial Pressure NR NR  
Cardiac Output 0 0  
Cardiac Index 0 0  
SVR ↓ 0  
Endocrine Response ↑ ↓  
 
Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify 





Kaushal, R. P., Vatal, A., & Pathak, R. (2015). Effect of etomidate and propofol induction on hemodynamic and endocrine response in 
patients undergoing coronary artery bypass grafting/mitral valve and aortic valve replacement surgery on cardiopulmonary bypass. 
Annals of Cardiac Anesthesia, 18(2), 172-178. https://doi.org/10.4103/0971-9784.154470 
 Propofol Etomidate Ketamine 
Heart Rate 0 0  
Systolic Blood Pressure ↓ 0  
Diastolic Blood Pressure ↓ 0  
Mean Arterial Pressure ↓ 0  
Cardiac Output ↓ 0  
Cardiac Index ↓ 0  
SVR ↓ 0  
Endocrine Response ↑ ↓  
 
Note: Arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify that the particular 




Shivanna, S., Priye, S., Jagannath, S., Kadli, C., Mayuri, M., Vikas, V., ... Reddy, D. (2015). A comparative study of haemodynamic 
effects of propofol and etomidate as an induction agent in coronary artery surgery. Journal of Evolution of Medical and Dental 
Sciences, 4(1), 2278-4748. https://doi.org/10.14260/jemds/2015/88 
 Propofol Etomidate Ketamine 
Heart Rate 0 0  
Systolic Blood Pressure NR NR  
Diastolic Blood Pressure NR NR  
Mean Arterial Pressure ↓ ↓  
Cardiac Output NR NR  
Cardiac Index 0 0  
SVR ↓ ↑ (post intubation)  
Endocrine Response NR NR  
 
Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify 





Kamath, M. R., Kamath, S., & Patla, K. P. (2016). Propofol or etomidate: Does it genuinely matter for induction in cardiac 
surgical procedures? Indian Journal of Clinical Anesthesia, 3(4), 551-555. https://doi.org/10.18231/2394-4994.2016.0012 
 Propofol Etomidate Ketamine 
Heart Rate 0 0  
Systolic Blood Pressure ↓ 0  
Diastolic Blood Pressure 0 0  
Mean Arterial Pressure ↓ 0  
Cardiac Output ↓ 0  
Cardiac Index ↓ 0  
SVR 0 0  
Endocrine Response NR NR  
 
Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify 





Soleimani, A., Heidari, N., Habibi, M. R., Kiabi, F. H., Khademloo, M., Zeydi, A. E., & Sohrabi, F. B. (2017). Comparing 
hemodynamic responses to diazepam, propofol and etomidate during anesthesia induction in patients with left ventricular dysfunction 
undergoing coronary artery bypass graft surgery: A double-blind, randomized clinical trial. Medical Archives, 71(3), 198-203. 
https://doi.org/10.5455/medarh.2017.71.198-203 
 Propofol Etomidate Ketamine 
Heart Rate ↓ ↓  
Systolic Blood Pressure ↓ 0  
Diastolic Blood Pressure ↓ 0  
Mean Arterial Pressure ↓ 0  
Cardiac Output NR NR  
Cardiac Index NR NR  
SVR NR NR  
Endocrine Response NR NR  
 
Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify 




Mala, R., & Narmada, S. (2017). Prospective randomised study comparing the haemodynamic and endocrine response to induction 
with etomidate and propofol in patients undergoing cardiac surgery on cardiopulmonary bypass. Indian Journal of Applied Research, 
7(10), 145-146. Retrieved from https://www.worldwidejournals.com/indian-journal-of-applied-research 
(IJAR)/fileview/October_2017_1506777489__54.pdf 
 Propofol Etomidate Ketamine 
Heart Rate ↓ ↓  
Systolic Blood Pressure ↓ 0  
Diastolic Blood Pressure 0 0  
Mean Arterial Pressure ↓ 0  
Cardiac Output NR NR  
Cardiac Index ↓ 0  
SVR NR NR  
Endocrine Response ↑ ↓  
 
Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify 




Meena, R., Sharma, R. S., Ranawat, P., Saiyed, A., & Verma, I. (2017). Comparison of hemodynamic and serum cortisol levels in 
response to anesthetic induction with etomidate or propofol in patients undergoing CABG surgery. Indian Journal of Clinical 
Anaesthesia, 4(3), 345-351. https://doi.org/10.18231/2394-4994.2017.0071 
 Propofol Etomidate Ketamine 
Heart Rate ↓ ↓  
Systolic Blood Pressure ↓ 0  
Diastolic Blood Pressure ↓ 0  
Mean Arterial Pressure ↓ 0  
Cardiac Output 0 0  
Cardiac Index 0 0  
SVR ↓ 0  
Endocrine Response ↑ ↓  
 
Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify 




Hannam, J. A., Mitchell, S. J., Cumin, D., Frampton, C., Merry, A. F., Moore, M. R., & Kruger, C. J. (2019). Haemodynamic profiles 
of etomidate vs propofol for induction of anaesthesia: A randomised controlled trial in patients undergoing cardiac surgery. British 
Journal of Anaesthesia, 122(2), 198-205. https://doi.org/10.1016/j.bja.2018.09.027 
 Propofol Etomidate Ketamine 
Heart Rate NR NR  
Systolic Blood Pressure NR NR  
Diastolic Blood Pressure NR NR  
Mean Arterial Pressure ↓ 0  
Cardiac Output NR NR  
Cardiac Index NR NR  
SVR NR NR  
Endocrine Response NR NR  
 
Note: NR-not reported, arrows represent statistically significant findings, zeroes represent lack of statistically significant findings, blacked out columns signify 






Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist 
Basagan-Mogol, E., Goren, S., Korfali, G., Turker, G., & Kaya, F. N. (2010). Induction 
of anesthesia in coronary artery bypass graft surgery: The hemodynamic and analgesic 
effects of ketamine. Clinics, 65(2), 133-138. 
https://doi.org/10.1590/S180759322010000200003 
  
D) Are the results of the trial valid? YES CAN’T TELL NO 
12. Did the trial address a clearly focused 
issue? X   
13. Was the assignment of patients to 
treatments randomized? X   
14. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
X   
15. Were patients, health workers, and 
study personnel “blind” to treatment?  X  
16. Were the groups similar at the start of 
the trial? X   
17. Aside from the experimental 
intervention, were groups treated 
equally? 
X   
E) What are the results?  
18. How large was the treatment effect? Not discussed 
19. How precise was the estimate of the 
treatment effect? 
Not discussed 
F) Will the results help locally? YES CAN’T TELL NO 
20. Can the results be applied in your 
context? (or to the local population?) X   
21. Were all clinically important outcomes 
considered? X   






Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist 
Pandey, A. K., Makhija, N., Chauhan, S., Das, S., Kiran, U., Bisoi, A. K., & Lakshmy, R. 
(2012). The effects of etomidate and propofol induction on hemodynamic and endocrine 
response in patients undergoing coronary artery bypass graft surgery on cardiopulmonary 
bypass. World Journal of Cardiovascular Surgery, 2(3), 48-53. 
https://doi.org/10.4236/wjcs.2012.23011 
 
A) Are the results of the trial valid? YES CAN’T TELL NO 
1. Did the trial address a clearly focused 
issue? X   
2. Was the assignment of patients to 
treatments randomized? X   
3. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers, and 
study personnel “blind” to treatment?  X  
5. Were the groups similar at the start of 
the trial? X   
6. Aside from the experimental 
intervention, were groups treated 
equally? 
X   
B) What are the results?  
7. How large was the treatment effect? Not discussed 
8. How precise was the estimate of the 
treatment effect? Not discussed 
C) Will the results help locally? YES CAN’T TELL NO 
9. Can the results be applied in your 
context? (or to the local population?) X 
  
10. Were all clinically important outcomes 
considered? X 
  






Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist 
Kaushal, R. P., Vatal, A., & Pathak, R. (2015). Effect of etomidate and propofol induction on 
hemodynamic and endocrine response in patients undergoing coronary artery bypass 
grafting/mitral valve and aortic valve replacement surgery on cardiopulmonary bypass. Annals of 
Cardiac Anesthesia, 18(2), 172-178. https://doi.org/10.4103/0971-9784.154470 
A) Are the results of the trial valid? YES CAN’T TELL NO 
1. Did the trial address a clearly focused 
issue? X   
2. Was the assignment of patients to 
treatments randomized? X   
3. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers, and 
study personnel “blind” to treatment?  X  
5. Were the groups similar at the start of 
the trial? X   
6. Aside from the experimental 
intervention, were groups treated 
equally? 
X   
B) What are the results?  
7. How large was the treatment effect? Not discussed 
8. How precise was the estimate of the 
treatment effect? Not discussed 
C) Will the results help locally? YES CAN’T TELL NO 
9. Can the results be applied in your 
context? (or to the local population?) X   
10. Were all clinically important outcomes 
considered? X   






Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist 
Shivanna, S., Priye, S., Jagannath, S., Kadli, C., Mayuri, M., Vikas, V., ... Reddy, D. 
(2015). A comparative study of haemodynamic effects of propofol and etomidate as an 
induction agent in coronary artery surgery. Journal of Evolution of Medical and Dental 
Sciences, 4(1), 2278-4748. https://doi.org/10.14260/jemds/2015/88 
 
A) Are the results of the trial valid? YES CAN’T TELL NO 
1. Did the trial address a clearly focused 
issue? X   
2. Was the assignment of patients to 
treatments randomized? X   
3. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers, and 
study personnel “blind” to treatment? X   
5. Were the groups similar at the start of 
the trial? X   
6. Aside from the experimental 
intervention, were groups treated 
equally? 
X   
B) What are the results?  
7. How large was the treatment effect? Not discussed 
8. How precise was the estimate of the 
treatment effect? Not discussed 
C) Will the results help locally? YES CAN’T TELL NO 
9. Can the results be applied in your 
context? (or to the local population?) X   
10. Were all clinically important outcomes 
considered? X   






Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist 
Kamath, M. R., Kamath, S., & Patla, K. P. (2016). Propofol or etomidate: Does it 
genuinely matter for induction in cardiac surgical procedures? Indian Journal of Clinical 
Anesthesia, 3(4), 551-555. https://doi.org/10.18231/2394-4994.2016.0012 
 
A) Are the results of the trial valid? YES CAN’T TELL NO 
1. Did the trial address a clearly focused 
issue? X   
2. Was the assignment of patients to 
treatments randomized? X   
3. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers, and 
study personnel “blind” to treatment?  X  
5. Were the groups similar at the start of 
the trial? X   
6. Aside from the experimental 
intervention, were groups treated 
equally? 
X   
B) What are the results?  
7. How large was the treatment effect? Not discussed 
8. How precise was the estimate of the 
treatment effect? Not discussed 
C) Will the results help locally? YES CAN’T TELL NO 
9. Can the results be applied in your 
context? (or to the local population?) X   
10. Were all clinically important outcomes 
considered? X   






Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist 
Soleimani, A., Heidari, N., Habibi, M. R., Kiabi, F. H., Khademloo, M., Zeydi, A. E., & 
Sohrabi, F. B. (2017). Comparing hemodynamic responses to diazepam, propofol and 
etomidate during anesthesia induction in patients with left ventricular dysfunction 
undergoing coronary artery bypass graft surgery: A double-blind, randomized clinical 
trial. Medical Archives, 71(3), 198-203. https://doi.org/10.5455/medarh.2017.71.198-203 
 
A) Are the results of the trial valid? YES CAN’T TELL NO 
1. Did the trial address a clearly focused 
issue? X   
2. Was the assignment of patients to 
treatments randomized? X   
3. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers, and 
study personnel “blind” to treatment? X   
5. Were the groups similar at the start of 
the trial? X   
6. Aside from the experimental 
intervention, were groups treated 
equally? 
X   
B) What are the results?  
7. How large was the treatment effect? Not discussed 
8. How precise was the estimate of the 
treatment effect? Not discussed 
C) Will the results help locally? YES CAN’T TELL NO 
9. Can the results be applied in your 
context? (or to the local population?) X   
10. Were all clinically important outcomes 
considered? X   






Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist 
Mala, R., & Narmada, S. (2017). Prospective randomised study comparing the 
Haemodynamic and endocrine response to induction with etomidate and propofol in 
patients undergoing cardiac surgery on cardiopulmonary bypass. Indian Journal of 






A) Are the results of the trial valid? YES CAN’T TELL NO 
1. Did the trial address a clearly focused 
issue? X   
2. Was the assignment of patients to 
treatments randomized? X   
3. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
 X  
4. Were patients, health workers, and 
study personnel “blind” to treatment?  X  
5. Were the groups similar at the start of 
the trial? X   
6. Aside from the experimental 
intervention, were groups treated 
equally? 
 X  
B) What are the results?  
7. How large was the treatment effect? Not discussed 
8. How precise was the estimate of the 
treatment effect? Not discussed 
C) Will the results help locally? YES CAN’T TELL NO 
9. Can the results be applied in your 
context? (or to the local population?) X   
10. Were all clinically important outcomes 
considered? X   




Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist 
Meena, R., Sharma, R. S., Ranawat, P., Saiyed, A., & Verma, I. (2017). Comparison of 
hemodynamic and serum cortisol levels in response to anesthetic induction with 
etomidate or propofol in patients undergoing CABG surgery. Indian Journal of Clinical 




A) Are the results of the trial valid? YES CAN’T TELL NO 
1. Did the trial address a clearly focused 
issue? X   
2. Was the assignment of patients to 
treatments randomized? X   
3. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers, and 
study personnel “blind” to treatment?  X  
5. Were the groups similar at the start of 
the trial? X   
6. Aside from the experimental 
intervention, were groups treated 
equally? 
X   
B) What are the results?  
7. How large was the treatment effect? Not discussed 
8. How precise was the estimate of the 
treatment effect? Not discussed 
C) Will the results help locally? YES CAN’T TELL NO 
9. Can the results be applied in your 
context? (or to the local population?) X   
10. Were all clinically important outcomes 
considered? X   




Critical Appraisal Skills Programme (CASP) Randomized Controlled Trials Checklist 
Hannam, J. A., Mitchell, S. J., Cumin, D., Frampton, C., Merry, A. F., Moore, M. R., & 
Kruger, C. J. (2019). Haemodynamic profiles of etomidate vs propofol for induction of 
anaesthesia: A randomised controlled trial in patients undergoing cardiac surgery. British 
Journal of Anaesthesia, 122(2), 198-205. https://doi.org/10.1016/j.bja.2018.09.027 
 
 
Note: This study was performed in two phases.  The patient was blinded during both 
phases.  Phase I was open-label for the anesthesia provider.  In phase II, the anesthesia 
provider was blinded to the treatment. 
  
A) Are the results of the trial valid? YES CAN’T TELL NO 
1. Did the trial address a clearly focused 
issue? X   
2. Was the assignment of patients to 
treatments randomized? X   
3. Were all of the patients who entered 
the trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers, and 
study personnel “blind” to treatment? X   
5. Were the groups similar at the start of 
the trial? X   
6. Aside from the experimental 
intervention, were groups treated 
equally? 
X   
B) What are the results?  
7. How large was the treatment effect? Not discussed 
8. How precise was the estimate of the 
treatment effect? Not discussed 
C) Will the results help locally? YES CAN’T TELL NO 
9. Can the results be applied in your 
context? (or to the local population?) X   
10. Were all clinically important outcomes 
considered? X   





AUTHOR / YEAR MEDICATION PROTOCOL RESULTS 
Study 1 
(Basagan-Mogol et al., 
2010) 
Group K: ketamine 2.0 mg/kg 
 
Group P: propofol 0.5 mg/kg 
Decreased MAP and SVR in group P one minute after induction 
Study 2 
(Pandey et al., 2012) 
Group E: etomidate 0.2 mg/kg 
 
Group p: propofol 2.0 mg/kg 
Decreased SBP, DBP, SVR, SVRI in group P five minutes after 
intubation 
 
More stable hemodynamics group E 
 
Decreased cortisol levels in group E at weaning from CPB 
 
Increased cortisol levels in group P at weaning from CPB 
Study 3 
(Kaushal et al., 2015) 
Group I: propofol 2.0 mg/kg 
 
Group II: etomidate 0.2 mg/kg 
Decreased SBP, DBP, MAP in group I 
 
Decreased SVR in both groups five minutes post induction 
 
Decreased cortisol level group II during/post CPB 
 
Increased cortisol level group I during/post CPB 
Study 4 
(Shivanna et al., 2015) 
Group P: propofol 0.5 
mg/kg/min 
 
Group E: etomidate 0.05 
mg/kg/min 





(Kamath et al., 2016) 
 
Group A: propofol 1.5 mg/kg 
 
Group B: etomidate 0.2 mg/kg 
Decreased SBP, MAP, CO and CI in group A after induction 
 
Increased DBP, CO, CI in group A after intubation 
 
Increased MAP, CVP, PCWP in group A five minutes after 
intubation 
Study 6 
(Soleimani et al., 2017) 
Group A: propofol 1.5 mg/kg 
 
Group B: etomidate 0.2 mg/kg 
 
Group C: diazepam 0.3 mg/kg 
Decreased SBP, DBP, MAP in all groups one minute after 
induction, remaining low longer in group A 
 
Larger number of patients in group A required rescue ephedrine 
administration 
Study 7 
(Mala & Narmala, 2017) 
Propofol group: propofol 2.0 
mg/kg 
 
Etomidate group: etomidate 0.2 
mg/kg 
Decrease in SBP in propofol group after induction, much lower 
five minutes after induction 
 
Decrease in CI two minutes and three minutes after induction in 
propofol group 
 
50% reduction in cortisol in etomidate group, nearly twofold 
increase in cortisol in propofol group 
Study 8 
(Meena et al., 2017) 
Group A: etomidate 0.3 mg/kg 
 
Group B: propofol 2.0 mg/kg 
Decreased cortisol group A, increased cortisol group B 
 
Decreased SBP, DBP, SVR, SVRI after induction group B 
 
Increased HR, SBP after intubation group A 
Study 9 
(Hannam et al., 2019) 
Propofol group: propofol titrated 
at anesthetist’s discretion to 
achieve loss of response to 
verbal command 
 
Etomidate group: etomidate 
titrated at anesthetist’s discretion 
34% greater reduction in MAP with propofol 
112 
 
to achieve loss of response to 
verbal command 
 
 
